Details of the Drug

General Information of Drug (ID: DM602WT)

Drug Name
Idelalisib
Synonyms
Idelalisib; 870281-82-6; CAL-101; Zydelig; GS-1101; CAL101; CAL 101; (S)-2-(1-((9H-Purin-6-yl)amino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; UNII-YG57I8T5M0; CAL-101 (Idelalisib, GS-1101); YG57I8T5M0; CHEMBL2216870; CHEBI:82701; 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one; AK145603; Idelalisib; CAL-101; (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one; 1146702-54-6; 5-FLUORO-3-PHENYL-2-[(1S)-1-(9H-PURIN-6-YLAMINO)PROPYL]-4(3H)-QUINAZOLINONE
Indication
Disease Entry ICD 11 Status REF
Chronic lymphocytic leukaemia 2A82.0 Approved [1]
Small lymphocytic lymphoma 2A82.0 Approved [2]
Follicular lymphoma 2A80 Investigative [2]
Affected Organisms
Humans and other mammals
ATC Code
L01EM01: Idelalisib
L01EM: Phosphatidylinositol-3-kinase (Pi3K) inhibitors
L01E: PROTEIN KINASE INHIBITORS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 415.4
Logarithm of the Partition Coefficient (xlogp) 3.7
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Clearance
The clearance of drug is 14.9 L/h []
Half-life
The concentration or amount of drug in body reduced by one-half in 8.2 hours [3]
Metabolism
The drug is metabolized via the aldehyde oxidase and CYP3A to its major metabolite GS-563117 []
Vd
The volume of distribution (Vd) of drug is 23 L []
Chemical Identifiers
Formula
C22H18FN7O
IUPAC Name
5-fluoro-3-phenyl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one
Canonical SMILES
CC[C@@H](C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5
InChI
InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1
InChIKey
IFSDAJWBUCMOAH-HNNXBMFYSA-N
Cross-matching ID
PubChem CID
11625818
ChEBI ID
CHEBI:82701
CAS Number
870281-82-6
UNII
YG57I8T5M0
DrugBank ID
DB09054
TTD ID
D0J5VR
VARIDT ID
DR00219
INTEDE ID
DR0854
ACDINA ID
D00322
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PI3-kinase delta (PIK3CD) TTGBPJE PK3CD_HUMAN Inhibitor [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Gene/Protein Processing [7]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Gene/Protein Processing [7]
Phosphoinositide-3-kinase-interacting protein 1 (PIK3IP1) OTWE5G4T P3IP1_HUMAN Gene/Protein Processing [8]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Post-Translational Modifications [8]
RNA cytidine acetyltransferase (NAT10) OT6JQO26 NAT10_HUMAN Gene/Protein Processing [9]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Protein Interaction/Cellular Processes [10]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Protein Interaction/Cellular Processes [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic lymphocytic leukaemia
ICD Disease Classification 2A82.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
PI3-kinase delta (PIK3CD) DTT PIK3CD 4.31E-16 -0.37 -0.91
Breast cancer resistance protein (ABCG2) DTP BCRP 1.20E-13 -1.20E+00 -1.06E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 7.29E-03 -3.47E-02 -1.80E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1 5.4294 10.179 2.2572 12.2872
ES7 GDSC1 0.6712 7.29 -0.7356 47.4652
ES5 GDSC1 3.4497 7.4794 1.9681 21.5187
EW-18 GDSC1 4.4545 7.2789 2.9524 10.3017
ES1 GDSC1 4.4892 10.8486 1.197 21.9554
ES6 GDSC1 4.5303 9.3692 1.9698 17.1553
EW-1 GDSC1 4.5366 8.9191 2.1997 15.5737
EW-11 GDSC1 4.5691 8.8135 2.2787 14.906
NOS-1 [Human HNSCC] GDSC1 4.713 10.1972 1.7035 18.2136
EW-7 GDSC1 4.8338 8.8478 2.4701 12.6377
CADO-ES1 GDSC1 4.8742 7.5721 3.131 7.5577
HuO9 GDSC1 5.1925 12.7761 0.7967 21.624
ES8 GDSC1 5.1973 10.4073 1.9744 14.8815
MHH-ES-1 GDSC1; CTRP2 5.2465 9.6002 3.5645 12.0637
ES4 GDSC1 5.4026 12.3041 1.1918 18.9171
CHSA8926 GDSC1 5.4981 10.8476 1.9798 13.9286
SK-PN-DW GDSC1 5.5082 8.9289 2.9163 7.4011
TC-71 GDSC1 5.5169 7.2093 3.7105 1.8504
SK-N-MC CTRP2 5.5924 6.5871 5.3424 3.9575
G-292 clone A141B1 GDSC1; CTRP2 5.6413 9.7741 3.8338 10.0949
SK-ES-1 GDSC1; CTRP2 5.7514 8.1327 4.7471 6.0462
EW-16 GDSC1 5.7643 9.6401 2.7474 7.9584
CHSA0011 GDSC1 5.8098 9.1951 2.9855 6.172
U2OS GDSC1; CTRP2 5.8951 9.196 4.3426 7.4462
A-673 GDSC1; CTRP2 5.9678 7.2112 5.396 2.877
SJSA-1 GDSC1; CTRP2 5.998 10.118 3.2517 6.2973
SaOS-2 GDSC1; CTRP2 6.0158 8.9283 4.5786 6.2165
H-EMC-SS GDSC1 6.0282 9.293 3.0733 5.0898
EW-3 GDSC1 6.0793 9.8561 2.8462 6.5291
MG-63 GDSC1; CTRP2 6.2782 9.6053 4.4549 6.2431
CAL-72 GDSC1 6.3955 8.0067 3.7923 0.5268
TC71 CTRP2 6.4623 7.8387 5.4671 1.7287
EW-13 GDSC1 6.4683 19.7129 -1.6662 27.1617
NY GDSC1 6.6192 9.9159 3.1278 3.2677
HOS GDSC1; CTRP2 6.6959 8.4409 5.3359 1.9302
EW-24 GDSC1 6.6961 7.9281 3.9293 0.1008
HuO-3N1 GDSC1 6.8228 16.3177 0.2588 19.4841
Hs 822.T CTRP2 6.8315 8.0031 5.6171 0.7311
Hs 888.T CTRP2 7.1846 13.7603 3.0906 10.291
CHSA0108 GDSC1 7.1898 9.5071 3.5567 0.8412
CAL-78 GDSC1; CTRP2 7.2156 11.3892 4.2739 5.4599
SW1353 CTRP2 9.5865 20.6419 1.4449 12.6419
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 213 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 5.3994 12.5769 2.2262 17.0732
JK1 CTRP2 5.4188 9.1807 3.9286 10.1769
JM1 GDSC1; CTRP2 6.598 13.0944 2.9695 11.7937
SU-DHL-6 GDSC1; CTRP2 -6.9433 0.1848 -7.0596 77.6394
Ri-1 CTRP2 -5.8949 10.2787 -8.3454 63.5588
HAL-01 GDSC1 -2.9457 5.4372 -3.9398 68.7638
NU-DUL-1 GDSC1; CTRP2 -2.2098 7.9433 -3.5454 53.3433
EB2 GDSC1 -1.5589 10.9781 -4.6318 57.856
YT GDSC1 -0.8192 12.0943 -4.3835 54.662
Ku812 GDSC1 -0.5168 2.4855 -0.5938 59.3609
DoHH2 CTRP2 -0.3633 12.7488 -3.4714 45.9338
Pfeiffer CTRP2 0.0246 11.7263 -2.629 44.0153
HH [Human lymphoma] GDSC1; CTRP2 0.1545 22.7658 -7.619 46.2482
Farage GDSC1 0.2999 5.5606 -0.4587 50.1881
QIMR-WIL GDSC1 0.3491 17.5731 -5.8488 49.9152
MV4-11 GDSC1; CTRP2 0.5952 11.2361 -1.8276 41.1775
P30/OHK GDSC1 0.9212 7.4026 -0.5227 45.5889
NALM-6 GDSC1; CTRP2 1.0026 9.7155 -0.7629 38.063
NKM-1 GDSC1 1.1946 7.4703 -0.2686 43.4377
NK-92MI GDSC1 1.2621 37.8839 -15.0725 48.5969
SU-DHL-10 GDSC1; CTRP2 1.3209 5.7461 0.9678 32.6151
HC-1 GDSC1 1.3932 20.7021 -6.4209 47.0076
KMS-26 CTRP2 1.729 3.897 1.7044 28.8319
Karpas-45 GDSC1 1.8376 6.5941 0.7736 36.4747
ARH-77 GDSC1 1.9352 9.6733 -0.5332 39.7699
BL-41 GDSC1 1.9556 8.0924 0.2266 37.6711
Hs 611.T CTRP2 2.0635 12.8742 -1.0699 35.2823
MLMA GDSC1 2.1196 12.5418 -1.742 41.1388
SU-DHL-5 GDSC1 2.1283 5.1287 1.6676 30.3005
NCI-H929 CTRP2 2.2192 5.5993 1.9824 26.2959
GA-10 CTRP2 2.2387 10.2641 0.2887 31.5999
Loucy GDSC1 2.3275 4.3093 2.1487 26.0888
CCRF-CEM GDSC1 2.3827 5.2342 1.9016 27.3731
MOLT-16 GDSC1; CTRP2 2.3887 5.3138 2.2279 24.9048
WIL2 NS GDSC1 2.4149 8.2256 0.6185 33.7897
PL-21 GDSC1 2.4177 6.6575 1.3428 30.4417
HT GDSC1; CTRP2 2.52 6.7693 1.9783 25.3768
LC4-1 GDSC1 2.7041 15.2011 -2.5184 40.0686
MOLM-16 CTRP2 2.7855 9.8746 1.0201 27.8309
EB1 CTRP2 2.8009 9.5904 1.161 27.3359
RCH-ACV CTRP2 2.8155 12.056 0.0544 30.5402
CESS GDSC1 2.8194 6.0664 2.0149 24.2598
ML-2 GDSC1 2.8225 8.007 1.1179 29.4615
KMS-27 CTRP2 2.8233 6.645 2.3485 23.1353
Kasumi-1 GDSC1; CTRP2 2.8276 8.1201 1.8094 25.0588
BL-70 CTRP2 2.9934 5.6027 2.8242 20.9095
WSU-DLCL2 GDSC1; CTRP2 3.0045 5.2841 2.8993 20.6114
OCI-Ly10 CTRP2 3.021 9.0434 1.6257 25.1464
KE-37 GDSC1; CTRP2 3.0931 6.0737 2.8155 20.6324
Kasumi-2 CTRP2 3.1086 12.8715 -0.0439 29.9916
EoL-1 GDSC1; CTRP2 3.1859 5.2591 3.0988 19.3404
Karpas-422 GDSC1; CTRP2 3.2993 7.7074 2.4738 21.2893
RS4;11 GDSC1; CTRP2 3.4396 15.2123 -1.4319 29.0618
RPMI-6666 GDSC1; CTRP2 3.4539 10.3319 1.4874 24.4302
P32/ISH GDSC1 3.4673 10.9634 0.2646 30.2822
Daudi GDSC1; CTRP2 3.4952 6.4656 3.1369 18.2547
OCI-AML-3 GDSC1; CTRP2 3.5538 8.6035 2.3661 20.9889
KMS-34 CTRP2 3.5826 6.817 3.1132 18.0866
NU-DHL-1 CTRP2 3.6294 11.5035 1.1107 25.2236
SUP-T11 CTRP2 3.6388 11.7909 0.9831 25.6094
THP-1 GDSC1; CTRP2 3.659 6.8319 3.1903 17.5777
GDM-1 GDSC1; CTRP2 3.6594 9.1261 2.2433 21.1654
Mono-Mac-1 CTRP2 3.6597 13.8909 -0.0084 28.457
NB4 GDSC1; CTRP2 3.7185 6.8696 3.241 17.2164
ALL-PO GDSC1 3.7392 9.5856 1.19 24.9075
697 GDSC1; CTRP2 3.7619 9.2398 2.2956 20.6981
EHEB CTRP2 3.8041 17.9702 -1.8749 32.3284
MOLP-8 GDSC1; CTRP2 3.828 8.2264 2.8123 18.5518
KE-97 CTRP2 3.8436 8.4121 2.7477 18.7586
MOLM-13 GDSC1; CTRP2 3.8542 9.6683 2.1921 20.845
KHM-1B CTRP2 3.9041 8.3687 2.8288 18.2851
VL51 GDSC1 3.9599 8.762 1.7934 20.4756
Mono-Mac-6 GDSC1; CTRP2 4.0401 12.5775 0.9871 24.576
ATN-1 GDSC1 4.1744 7.5115 2.6026 13.9958
PL21 CTRP2 4.2083 8.8904 2.9033 17.2055
MOLT-4 GDSC1 4.2973 6.6699 3.1274 9.502
NOMO-1 GDSC1; CTRP2 4.3103 11.427 1.7997 21.1423
Ki-JK CTRP2 4.3107 8.2397 3.3014 15.3734
KMS-12-BM GDSC1; CTRP2 4.312 7.4802 3.6329 14.0664
TUR GDSC1 4.3236 6.5628 3.2029 8.8143
SU-DHL-4 GDSC1; CTRP2 4.388 8.4959 3.2636 15.3256
PF-382 GDSC1; CTRP2 4.4006 9.3019 2.9027 16.7261
A4/Fukuda GDSC1; CTRP2 4.4463 7.2614 3.8647 12.8017
Jurkat CTRP2 4.4529 7.7308 3.6716 13.5409
MM1.S CTRP2 4.465 8.0803 3.5294 14.0728
GR-ST GDSC1 4.5333 7.7864 2.7625 11.4824
BC-3 GDSC1 4.5526 5.961 3.6858 4.2407
SUP-M2 GDSC1; CTRP2 4.5727 7.1278 4.0525 11.7295
ALL-SIL GDSC1; CTRP2 4.5738 8.2241 3.5741 13.6179
MC116 GDSC1; CTRP2 4.6663 6.3082 4.4609 9.9122
SU-DHL-16 GDSC1 4.7017 6.1775 3.6884 3.7774
VAL GDSC1 4.7135 12.8532 0.3781 25.1412
Reh GDSC1; CTRP2 4.7626 11.1435 2.3611 17.9775
RPMI-8402 GDSC1; CTRP2 4.773 8.5633 3.6147 12.9607
MHH-CALL-4 CTRP2 4.8173 11.9119 2.0343 19.0851
U-937 CTRP2 4.8251 6.6956 4.4928 9.3372
JSC-1 GDSC1 4.8448 7.8417 2.9765 8.8282
TK [Human B-cell lymphoma] GDSC1 4.8941 8.5102 2.6834 10.8802
BC-1 GDSC1 4.9367 9.4272 2.2618 13.7786
MHH-CALL-3 CTRP2 4.9432 16.7138 -0.2337 26.0284
BALL-1 GDSC1 4.9694 6.9419 3.5044 4.4447
CTV-1 GDSC1 5.0149 8.4084 2.8235 9.4627
P31/FUJ GDSC1; CTRP2 5.0654 8.5445 3.9075 11.0677
CA46 GDSC1; CTRP2 5.0815 10.3276 3.0555 14.5103
RL GDSC1; CTRP2 5.0857 7.9568 4.2062 9.8002
KMS-21-BM CTRP2 5.0904 8.1074 4.1398 10.0592
KMOE-2 GDSC1 5.121 10.1843 2.0272 14.7768
LP-1 GDSC1; CTRP2 5.1222 7.7788 4.3254 9.2275
BE-13 GDSC1 5.1728 8.7591 2.7663 9.4192
Mino CTRP2 5.1753 8.2416 4.158 9.7827
JVM-2 GDSC1; CTRP2 5.1776 20.5882 -1.9619 29.525
OPM-2 GDSC1 5.1802 8.8382 2.7329 9.6431
RPMI-8866 GDSC1 5.1897 7.3463 3.4573 4.2406
SU-DHL-1 GDSC1; CTRP2 5.1984 6.9811 4.7655 7.2684
MHH-PREB-1 GDSC1 5.214 7.0865 3.5934 3.205
ST486 GDSC1; CTRP2 5.2162 7.7461 4.4331 8.5612
KMS-11 GDSC1; CTRP2 5.2301 8.5665 4.0538 10.0831
HuT 78 CTRP2 5.2308 8.8395 3.922 10.6247
LAMA-84 GDSC1 5.2821 8.9915 2.7309 9.3638
MN-60 GDSC1 5.2839 11.5361 1.4818 17.6549
KCL-22 GDSC1 5.2952 8.0956 3.1716 6.0799
MOLT-3 CTRP2 5.3377 7.2758 4.7727 6.8867
SK-MM-2 GDSC1; CTRP2 5.3457 13.41 1.7643 18.8962
RPMI-8226 GDSC1; CTRP2 5.3636 8.9262 4.0031 9.99
Sc-1 GDSC1 5.3999 9.3369 2.6461 9.6452
M-07e CTRP2 5.4093 9.4995 3.7627 10.8857
KMS-28BM CTRP2 5.4118 9.6472 3.692 11.1733
EM-2 GDSC1; CTRP2 5.4416 10.2759 3.4075 12.2839
KMS-20 CTRP2 5.4637 7.7319 4.6786 6.9698
P12-Ichikawa GDSC1; CTRP2 5.4767 9.7172 3.7158 10.9346
Namalwa GDSC1; CTRP2 5.5189 10.4047 3.4122 12.1
NCO2 CTRP2 5.5222 8.7717 4.2243 8.7215
MEG-01 GDSC1 5.5245 8.7401 3.0167 6.6323
SUP-T1 GDSC1; CTRP2 5.5545 8.6825 4.2977 8.3452
Hs 445 GDSC1 5.558 16.3046 -0.673 26.5238
SCC-3 GDSC1 5.5939 6.8808 3.8835 0.7902
L-540 GDSC1; CTRP2 5.612 7.9504 4.7107 6.5005
SUP-HD1 GDSC1; CTRP2 5.6155 7.9074 4.7351 6.3914
SET-2 CTRP2 5.6513 7.9187 4.7624 6.1989
SKM-1 CTRP2 5.6656 6.5231 5.4455 3.3589
JeKo-1 CTRP2 5.6866 13.0586 2.2349 16.4352
KOPN-8 GDSC1 5.6911 12.9205 1.1035 18.5163
OCI-AML-2 GDSC1; CTRP2 5.6914 8.2763 4.6221 6.6965
MOLT-13 GDSC1; CTRP2 5.6924 7.4743 5.0184 5.0437
AML-193 CTRP2 5.707 8.0603 4.7431 6.1579
WSU-NHL GDSC1 5.7143 10.6458 2.2318 11.6484
KMS-18 CTRP2 5.7325 10.137 3.7327 10.3275
BV-173 GDSC1; CTRP2 5.7405 8.8475 4.3822 7.5959
Peer CTRP2 5.743 7.7381 4.9349 5.2797
DB GDSC1; CTRP2 5.7696 7.2706 5.1896 4.1612
HL-60 GDSC1; CTRP2 5.7988 10.4936 3.612 10.6942
ME1 GDSC1 5.8074 9.1938 2.9846 6.1841
L-1236 GDSC1; CTRP2 5.8266 10.849 3.4582 11.2748
KY821 GDSC1 5.8342 7.7216 3.6557 1.7035
KM-H2 GDSC1; CTRP2 5.8355 11.3427 3.2192 12.2391
TALL-1 [Human adult T-ALL] CTRP2 5.836 9.9773 3.9017 9.4121
SEM CTRP2 5.845 8.9127 4.4408 7.1352
BCP-1 CTRP2 5.9307 8.1012 4.9197 4.9516
F-36P CTRP2 5.9417 8.2279 4.8659 5.1556
MOLM-6 CTRP2 5.973 8.4171 4.798 5.3784
CMK CTRP2 5.9754 6.9407 5.5375 2.2674
L-363 GDSC1; CTRP2 5.9817 7.119 5.4539 2.6057
K-562 GDSC1; CTRP2 5.9858 7.5027 5.2658 3.3874
Ci-1 CTRP2 5.9912 8.6603 4.6919 5.7887
SIG-M5 GDSC1; CTRP2 6.0338 11.423 3.3462 11.3257
TF-1 CTRP2 6.0482 7.017 5.5613 2.0233
HD-MY-Z CTRP2 6.0851 7.3093 5.4455 2.4398
CML-T1 CTRP2 6.0989 8.0486 5.0873 3.9188
DEL GDSC1; CTRP2 6.1087 8.9199 4.6599 5.6967
H9 GDSC1 6.1273 11.3184 2.1897 10.8299
EJM GDSC1; CTRP2 6.1295 8.3395 4.967 4.3672
HEL GDSC1; CTRP2 6.1338 8.8727 4.704 5.4639
ME1 CTRP2 6.1523 8.6523 4.8293 4.9031
HEL 92.1.7 CTRP2 6.1612 7.1048 5.6081 1.6202
OCI-M1 GDSC1; CTRP2 6.1638 7.2268 5.5496 1.8606
KO52 CTRP2 6.1671 8.2777 5.0283 4.0401
MY-M12 GDSC1 6.1715 12.1002 1.8454 12.897
ROS-50 GDSC1 6.194 8.6825 3.4333 2.4781
Karpas-299 GDSC1; CTRP2 6.239 9.2876 4.582 5.7815
Ramos.2G6.4C10 GDSC1 6.2511 12.8994 1.5151 14.6541
JVM-3 GDSC1; CTRP2 6.2571 13.3974 2.5436 14.1107
OCI-Ly3 CTRP2 6.3166 7.9632 5.3013 2.6356
HPB-ALL CTRP2 6.3474 9.8906 4.3676 6.4837
OCI-Ly19 GDSC1; CTRP2 6.3559 9.5642 4.5369 5.7601
RC-K8 GDSC1 6.3727 7.8858 3.8273 0.4273
Toledo CTRP2 6.3751 16.9951 0.8421 19.9174
Raji GDSC1; CTRP2 6.3846 7.8732 5.3957 2.136
Granta-519 GDSC1; CTRP2 6.4825 13.9904 2.4303 14.1203
REC-1 CTRP2 6.4835 10.1951 4.3226 6.4318
JJN-3 GDSC1; CTRP2 6.4875 9.6913 4.5758 5.3687
MOLP-2 CTRP2 6.4877 9.2266 4.806 4.41
KG-1 GDSC1 6.4959 13.9085 1.1972 15.7772
L-428 GDSC1; CTRP2 6.5038 8.6941 5.0802 3.2475
DND-41 GDSC1; CTRP2 6.5574 13.8848 2.5431 13.5464
DG-75 GDSC1 6.5897 8.7011 3.6115 1.0836
HDLM-2 GDSC1; CTRP2 6.5939 13.2721 2.8777 12.1665
KYO-1 CTRP2 6.6186 9.0088 5.0092 3.3601
HuNS1 CTRP2 6.6472 9.1693 4.9513 3.5535
Jiyoye GDSC1 6.7304 8.3544 3.7956 0.3484
Karpas-620 GDSC1; CTRP2 6.7859 14.3339 2.5002 13.2943
SR GDSC1; CTRP2 6.797 8.8243 5.2205 2.2512
MOTN-1 CTRP2 6.8619 10.966 4.2272 6.1952
U266B1 GDSC1; CTRP2 6.8933 10.5429 4.4574 5.1989
JURL-MK1 GDSC1; CTRP2 6.9287 8.9209 5.2593 1.9328
CTB-1 GDSC1 6.9481 8.815 3.7139 0.4722
U-698-M GDSC1 6.9656 8.5874 3.8001 0.2533
P3HR-1 CTRP2 6.9798 14.3641 2.6361 12.4256
SUP-B15 GDSC1; CTRP2 7.0339 19.3479 0.1982 20.6396
AMO1 GDSC1; CTRP2 7.037 10.2256 4.712 3.9494
KMM-1 CTRP2 7.142 12.7247 3.569 8.4386
SU-DHL-8 GDSC1; CTRP2 7.3612 27.7115 -3.7123 28.7693
A3/Kawakami GDSC1; CTRP2 7.4537 8.4198 5.7308 0.1165
OCI-AML-5 GDSC1; CTRP2 9.5074 19.5801 1.8995 11.2243
⏷ Show the Full List of 213 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 28 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 5.9407 9.4372 4.2608 7.6986
TE8 CTRP2 6.3544 10.289 4.1746 7.279
TE-6 GDSC1; CTRP2 5.0759 9.1826 3.0015 9.1276
TE-15 GDSC1 5.08 8.4435 2.8537 9.0439
TE-5 GDSC1; CTRP2 5.2545 7.3246 4.6674 7.5181
KYSE-70 GDSC1; CTRP2 5.7534 7.9729 4.8281 5.7035
TE-8 GDSC1 5.7815 9.7357 2.7134 8.1546
OE21 GDSC1; CTRP2 5.8094 7.1602 5.2803 3.6958
TE-10 GDSC1; CTRP2 5.982 8.8717 4.5784 6.2832
TE-4 GDSC1 5.9891 8.1018 3.5741 1.954
EC-GI-10 GDSC1; CTRP2 6.0379 7.3434 5.3895 2.7655
KYSE-140 GDSC1; CTRP2 6.1161 9.7289 4.2616 7.3554
TE-11 GDSC1; CTRP2 6.1183 7.8679 5.1935 3.4366
KYSE-410 GDSC1; CTRP2 6.298 10.1273 4.2102 7.2321
OE19 GDSC1; CTRP2 6.3171 7.2257 5.6626 1.1485
TE-1 GDSC1; CTRP2 6.3621 8.8663 4.8887 4.2781
OE33 GDSC1; CTRP2 6.7198 12.556 3.3329 10.1107
KYSE-180 GDSC1; CTRP2 6.7303 13.0959 3.0727 11.1431
TE-14 CTRP2 6.7566 10.3072 4.4735 5.3487
KYSE-450 GDSC1; CTRP2 6.8923 9.868 4.7848 3.8644
TE-9 GDSC1; CTRP2 6.894 9.4292 4.997 3.0076
COLO 680N GDSC1; CTRP2 6.987 9.6135 4.971 2.9838
T.T GDSC1 7.0613 8.7887 3.765 0.2968
KYSE-520 GDSC1; CTRP2 7.2771 12.2822 3.8836 6.9495
KYSE-150 GDSC1; CTRP2 7.3149 9.9832 5.0062 2.4355
KYSE-270 GDSC1 7.3156 9.058 3.7632 0.2248
KYSE-510 GDSC1; CTRP2 7.878 11.9201 4.4577 3.8487
KYSE-30 CTRP2 9.7185 17.433 3.0428 6.9262
⏷ Show the Full List of 28 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 40 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 6.8197 10.4893 4.4303 5.4258
KP-1N GDSC1 3.5781 5.6493 2.3889 6.8597
MZ-PC-1 GDSC1 5.3094 9.0034 2.7443 8.2378
HuP-T4 GDSC1; CTRP2 5.4594 10.2418 3.4403 12.1109
PL4 GDSC1 5.5615 8.3959 3.202 4.6556
BxPC-3 GDSC1; CTRP2 5.705 9.7793 3.8871 9.7405
Hs 766T GDSC1; CTRP2 5.798 11.132 3.2925 12.0148
PK-59 CTRP2 5.9204 10.3271 3.7988 9.6729
TCC-Pan2 CTRP2 5.9433 8.6584 4.6522 6.05
PK-45H CTRP2 6.1553 14.5968 1.8603 16.8794
PaTu 8988s CTRP2 6.179 9.3138 4.5204 6.1504
Panc 05.04 CTRP2 6.1879 13.9257 2.2227 15.4737
L3.3 CTRP2 6.237 10.5802 3.935 8.4958
Panc 08.13 GDSC1; CTRP2 6.2848 11.2469 3.6406 9.6318
KP-3 GDSC1; CTRP2 6.3003 11.6067 3.4735 10.2937
MIA PaCa-2 GDSC1; CTRP2 6.335 9.2755 4.6642 5.2643
DAN-G GDSC1; CTRP2 6.3997 8.584 5.0571 3.5125
SW1990 GDSC1; CTRP2 6.4223 8.6903 5.0216 3.6226
AsPC-1 GDSC1; CTRP2 6.4481 12.8211 2.9863 12.0012
PaTu 8988t GDSC1; CTRP2 6.4775 9.8979 4.4656 5.8454
Capan-1 GDSC1; CTRP2 6.556 9.0942 4.922 3.8174
KP-4 GDSC1; CTRP2 6.5952 11.8216 3.601 9.2327
Panc 03.27 GDSC1; CTRP2 6.6018 9.5378 4.7377 4.5059
PSN1 GDSC1; CTRP2 6.6087 9.9832 4.5233 5.3834
YAPC GDSC1; CTRP2 6.6725 9.0423 5.0312 3.1885
SU.86.86 GDSC1; CTRP2 6.8055 11.4245 3.9593 7.3931
Panc 04.03 GDSC1; CTRP2 6.8403 8.9997 5.1657 2.41
HPAF-II GDSC1; CTRP2 6.9432 13.0645 3.2524 10.0502
HPAC GDSC1; CTRP2 6.9717 12.8533 3.3785 9.4921
HuP-T3 GDSC1; CTRP2 7.0131 12.7244 3.4733 9.0385
PaTu 8902 GDSC1; CTRP2 7.2578 8.728 5.5281 0.6735
Panc 10.05 GDSC1; CTRP2 7.4533 14.9493 2.7046 11.3583
QGP-1 GDSC1; CTRP2 7.4773 10.0186 5.0862 1.9605
SNU-213 CTRP2 7.586 17.5605 1.5152 15.4828
KP-2 GDSC1; CTRP2 7.6775 12.6913 3.9637 6.0403
SUIT-2 GDSC1; CTRP2 8.023 13.0861 4.0044 5.4139
Panc 02.03 GDSC1; CTRP2 8.2023 13.0215 4.1482 4.6354
Capan-2 GDSC1; CTRP2 8.2835 15.7303 2.9166 9.2638
SNU-410 CTRP2 8.6543 16.3435 2.8739 8.8999
CFPAC-1 GDSC1; CTRP2 9.0815 15.2598 3.6544 5.4458
⏷ Show the Full List of 40 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 76 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SH4 CTRP2 9.5914 25.5158 -0.9168 19.4903
CHL-1 GDSC1 3.6542 6.9892 2.3978 17.6292
WM115 GDSC1; CTRP2 4.3214 10.8825 2.0732 20.1143
IST-MEL1 GDSC1 4.5198 13.6656 -0.1861 28.047
WM266-4 CTRP2 4.8519 10.3068 2.8529 15.8462
WM35 GDSC1 4.8594 7.7289 3.043 8.2757
MZ-MEL-2 GDSC1 5.0665 7.8802 3.1186 7.0915
COLO 792 GDSC1; CTRP2 5.1014 8.5096 3.9588 10.7729
WM1552C GDSC1 5.1084 10.6894 1.7675 16.488
LB2518-MEL GDSC1 5.1832 7.392 3.4317 4.4442
COLO 679 GDSC1 5.3213 8.77 2.8657 8.2673
G-mel GDSC1 5.3275 9.1634 2.6794 9.6088
A-431 GDSC1 5.5053 12.111 1.3643 17.6439
MMAc-SF GDSC1 5.5297 9.367 2.7211 8.7514
GAK GDSC1 5.6289 9.0094 2.9573 6.8019
A-388 GDSC1 5.6435 7.9621 3.4496 3.3139
WM88 CTRP2 5.67 12.8933 2.3031 16.2099
COLO 783 GDSC1 5.7692 7.5232 3.706 1.5082
LB373-MEL-D GDSC1 5.7917 7.7285 3.6315 1.9045
VMRC-MELG GDSC1 5.8845 7.7389 3.6731 1.5385
Hs 852.T CTRP2 5.9009 13.0622 2.4152 15.3081
CP50-MEL-B GDSC1 5.9976 7.503 3.818 0.7118
HMV-II GDSC1 6.0346 10.6183 2.4611 9.2622
Hs 294T CTRP2 6.0593 10.8357 3.6611 9.9747
M14 GDSC1 6.0609 8.1178 3.6027 1.6965
MZ-MEL-7 GDSC1 6.0698 10.2994 2.634 8.0016
RPMI-7951 GDSC1; CTRP2 6.1171 10.914 3.6699 9.8266
WM278 GDSC1 6.1528 10.9818 2.3663 9.6047
LOX-IMVI GDSC1; CTRP2 6.1829 8.0205 5.1693 3.4196
WT2-iPS GDSC1 6.2441 7.4553 3.9315 0.2077
SH-4 GDSC1 6.2472 8.5891 3.499 2.025
RVH-421 GDSC1; CTRP2 6.2496 13.1996 2.6363 13.7632
COLO 800 GDSC1; CTRP2 6.2741 9.1686 4.6694 5.3514
Mel Ho GDSC1; CTRP2 6.3325 16.0372 1.286 18.5445
CJM [Human melanoma] CTRP2 6.3499 10.362 4.1347 7.4539
HMCB CTRP2 6.3662 7.6402 5.4962 1.7524
Hs 934.T CTRP2 6.4358 16.4755 1.1513 18.7957
G-361 GDSC1; CTRP2 6.4533 11.2257 3.7861 8.7202
WM1799 CTRP2 6.4865 11.2713 3.7896 8.6459
CP66-MEL GDSC1 6.5489 8.0062 3.8507 0.2838
Hs 938.T GDSC1 6.5655 7.8692 3.9039 0.1491
Hs 940.T GDSC1; CTRP2 6.5948 11.8244 3.5993 9.2402
A2058 GDSC1; CTRP2 6.6179 8.6247 5.1953 2.6021
IGR-39 CTRP2 6.6691 11.1246 4.0043 7.4367
MeWo GDSC1; CTRP2 6.695 10.6523 4.2576 6.3426
Hs 895.T CTRP2 6.7274 12.2369 3.4973 9.4266
Mel JuSo GDSC1; CTRP2 6.7366 9.8041 4.7056 4.4237
Hs 944.T CTRP2 6.7622 17.4873 0.9096 18.9662
WM983B CTRP2 6.8148 11.344 4.0061 7.1844
DJM-1 GDSC1 6.8233 8.7353 3.6945 0.5973
451Lu GDSC1 6.8854 8.5981 3.7672 0.3568
IGR-1 GDSC1; CTRP2 6.9295 9.3915 5.0386 2.7935
SK-MEL-1 GDSC1; CTRP2 7.0731 9.2953 5.1753 2.0797
UACC-62 GDSC1; CTRP2 7.0857 11.0346 4.3548 5.3247
SK-MEL-28 GDSC1; CTRP2 7.1227 8.8658 5.3987 1.2081
MDA-MB-435S CTRP2 7.1231 12.6209 3.6061 8.3189
A-375 GDSC1; CTRP2 7.181 12.4863 3.7146 7.7855
K029AX CTRP2 7.205 13.703 3.1341 10.0845
SK-MEL-2 GDSC1; CTRP2 7.4106 8.4073 5.719 0.1451
HT-144 GDSC1; CTRP2 7.4126 12.3866 3.9285 6.5639
SK-MEL-30 GDSC1; CTRP2 7.4503 11.9116 4.1836 5.4841
Malme-3M CTRP2 7.4568 14.3265 3.0134 10.1512
A101D GDSC1; CTRP2 7.6935 12.9083 3.8705 6.3881
SK-MEL-3 GDSC1; CTRP2 8.0306 14.6307 3.2726 8.2596
SK-MEL-24 GDSC1; CTRP2 8.1321 14.1678 3.5632 6.9852
UACC-257 GDSC1; CTRP2 8.1648 14.4606 3.4453 7.3981
SK-MEL-31 CTRP2 8.3556 14.8799 3.3725 7.4171
WM793 GDSC1; CTRP2 8.582 16.9125 2.5521 10.1983
Hs 936.T CTRP2 8.7233 15.4781 3.3296 7.0934
Hs 688(A).T CTRP2 8.7935 20.5668 0.9273 15.4733
SK-MEL-5 GDSC1; CTRP2 8.8115 14.6362 3.777 5.306
IGR-37 GDSC1; CTRP2 9.1683 17.5332 2.6483 9.0358
IPC-298 GDSC1; CTRP2 9.2224 16.4196 3.2055 6.9284
Hs 839.T CTRP2 9.2781 19.9792 1.553 12.7174
COLO 829 GDSC1; CTRP2 9.4148 18.4421 2.3792 9.6756
EquiPSC Line K2 GDSC1 6.0628 8.9105 3.2646 3.7485
⏷ Show the Full List of 76 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYAE-1 GDSC1 3.9255 7.7446 2.2699 17.4067
OACM5.1 C GDSC1 4.3651 8.1395 2.449 14.4178
KYSE-50 GDSC1 4.6329 9.1362 2.1687 15.4482
OACP4 C GDSC1 4.877 8.7803 2.5367 12.0139
SK-GT-4 GDSC1 5.5698 8.902 2.9696 6.8596
TE-12 GDSC1 5.5911 9.0015 2.9365 7.0449
KYSE-220 GDSC1 5.622 10.978 2.0053 13.4018
ESO-26 GDSC1 5.6528 7.3879 3.7046 1.6787
ESO-51 GDSC1 5.8398 7.9002 3.5834 2.1187
FLO-1 GDSC1 5.9685 12.4125 1.5532 15.2039
HCE-4 GDSC1 6.0106 8.4391 3.442 2.711
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; CTRP2 4.9726 12.5898 1.8405 19.4434
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SJNB-5 GDSC1 4.2932 5.7988 3.5594 6.1181
CHP-212 GDSC1; CTRP2 4.4479 6.7886 4.0544 12.0674
NB69 GDSC1 4.5412 7.5754 2.8742 10.6034
KP-N-YS GDSC1 4.8124 8.5658 2.5936 11.8073
SK-N-DZ GDSC1; CTRP2 5.0865 7.809 4.2761 9.5147
GI-ME-N GDSC1 5.1365 9.1613 2.543 11.1557
NH-12 GDSC1 5.1797 8.1541 3.065 7.1789
NB(TU)1 GDSC1 5.2949 9.9468 2.2734 12.5766
TGW GDSC1 5.3854 9.2052 2.6997 9.2995
SJNB-6 GDSC1 5.5073 10.7205 2.0487 13.453
SK-N-MC-IXC GDSC1 5.5746 6.8568 3.8843 0.8063
LA-N-6 GDSC1 5.5899 7.7277 3.5236 2.9217
IMR-5 GDSC1 5.6519 7.73 3.557 2.5908
SJNB-12 GDSC1 5.6546 8.7075 3.1152 5.6136
NB1 CTRP2 5.7756 7.3245 5.1685 4.2357
MHH-NB-11 GDSC1; CTRP2 5.8093 13.2442 2.2467 16.1381
GOTO GDSC1 5.8741 7.8738 3.6119 1.8989
SK-N-SH GDSC1; CTRP2 5.9603 9.3593 4.3163 7.427
SJNB-13 GDSC1 5.9792 7.9069 3.6498 1.5445
IMR-32 CTRP2 6.0074 7.1494 5.4608 2.5253
NH-6 CTRP2 6.0427 8.5897 4.7703 5.3587
Kelly GDSC1; CTRP2 6.0492 7.3623 5.3895 2.7435
SK-N-BE(2) CTRP2 6.0528 9.0949 4.5261 6.3655
SJNB-7 GDSC1 6.0672 8.6485 3.3816 2.9932
SJNB-17 GDSC1 6.1122 9.5657 2.9991 5.4177
SJNB-10 GDSC1 6.1346 7.8759 3.7334 0.958
CHP-134 GDSC1 6.236 7.7518 3.8226 0.5218
KP-N-SI9s CTRP2 6.2536 8.6554 4.9089 4.3841
SK-N-FI GDSC1; CTRP2 6.2582 7.7941 5.3407 2.5699
SiMa GDSC1 6.3961 8.7964 3.4858 1.9045
SK-N-BE(2)-M17 GDSC1 6.4135 8.7188 3.5256 1.6739
CHP-126 CTRP2 6.4729 9.4535 4.6825 4.949
SJNB-14 GDSC1 6.5069 8.1799 3.7729 0.5251
KP-N-YN GDSC1; CTRP2 6.5262 8.1764 5.3483 2.1162
SK-N-AS GDSC1; CTRP2 6.7542 10.2469 4.5013 5.2375
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-478 CTRP2 2.5442 7.7833 1.6406 26.4856
SNU-1079 CTRP2 4.9043 8.7058 3.6752 12.3983
SNU-308 CTRP2 5.3414 9.5775 3.6625 11.4493
HuH-28 CTRP2 6.0024 11.1661 3.4485 10.9661
HuCC-T1 GDSC1; CTRP2 6.0751 11.0597 3.5622 10.3543
SNU-1196 CTRP2 6.2631 7.8923 5.2958 2.7492
SNU-869 CTRP2 7.3226 11.6751 4.21 5.5612
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Evsa-T GDSC1 4.0057 7.0554 2.6835 14.0459
YMB-1-E GDSC1 4.663 9.1749 2.1735 15.3101
HCC1599 GDSC1 4.7374 8.1844 2.7251 11.0752
HCC1187 GDSC1 4.7537 7.6717 2.9918 8.9976
MDA-MB-468 GDSC1; CTRP2 4.8291 8.8812 3.5191 13.2126
HCC1569 GDSC1 4.9601 11.9729 1.0144 21.2854
ZR-75-1 CTRP2 5.0676 13.4426 1.5028 20.4316
ZR-75-30 GDSC1; CTRP2 5.1184 9.4822 3.5037 12.601
OCUB-M GDSC1 5.1344 8.8956 2.6718 10.2263
MDA-MB-361 GDSC1; CTRP2 5.2025 8.1991 4.2045 9.5278
MDA-MB-175-VII GDSC1 5.373 7.3908 3.5498 2.8307
HCC1395 GDSC1; CTRP2 5.4424 9.2789 3.9016 10.2373
MCF-7 GDSC1; CTRP2 5.4457 7.5327 4.757 6.6896
MDA-MB-415 GDSC1 5.4521 10.1136 2.3054 10.7267
EFM-19 GDSC1 5.4989 11.8503 1.488 16.953
UACC-812 GDSC1 5.5021 9.7432 2.5207 10.2514
HCC1143 CTRP2 5.5649 12.0394 2.6385 15.1282
MDA-MB-330 GDSC1 5.5917 9.3712 2.761 8.3025
AU565 GDSC1; CTRP2 5.5969 8.0636 4.6413 6.8225
HCC1954 GDSC1; CTRP2 5.6848 8.0564 4.725 6.2812
SK-BR-3 CTRP2 5.7044 21.8722 -2.1546 28.866
CAMA-1 GDSC1; CTRP2 5.7525 8.369 4.6307 6.5306
CAL-51 GDSC1; CTRP2 5.7872 9.093 4.3008 7.8403
HCC2218 GDSC1; CTRP2 5.8482 9.0083 4.3959 7.3169
EFM-192A GDSC1; CTRP2 5.8907 7.0887 5.3892 3.0655
Hs 578T GDSC1; CTRP2 5.9314 8.8172 4.5628 6.4493
COLO 824 GDSC1 6.0656 10.3039 2.6292 8.0446
HCC2157 GDSC1 6.0976 7.9655 3.6816 1.2406
HCC1419 GDSC1; CTRP2 6.1153 11.2205 3.5152 10.4716
MRK-nu-1 GDSC1 6.1331 7.5417 3.8588 0.4617
DU4475 GDSC1; CTRP2 6.1369 7.5388 5.3728 2.6491
T-47D GDSC1; CTRP2 6.1712 12.4845 2.9294 12.7523
MFM-223 GDSC1 6.1973 8.5346 3.497 2.104
HCC1500 GDSC1; CTRP2 6.2354 7.6969 5.3714 2.481
BT-483 GDSC1 6.2476 11.4645 2.1998 10.4623
BT-20 GDSC1; CTRP2 6.3052 7.6533 5.4455 2.0564
CAL-148 GDSC1; CTRP2 6.3793 8.3371 5.1638 3.1032
CAL-120 GDSC1; CTRP2 6.3828 8.9762 4.85 4.404
HCC1806 GDSC1; CTRP2 6.3948 9.1411 4.7775 4.6859
HMC-1-8 CTRP2 6.4448 9.7121 4.5326 5.6224
BT-474 GDSC1; CTRP2 6.4678 9.5133 4.6489 5.0976
HDQ-P1 GDSC1; CTRP2 6.4694 10.1484 4.3349 6.405
HCC70 GDSC1 6.4916 18.0466 -0.8268 23.1312
MDA-MB-453 GDSC1; CTRP2 6.4933 9.1151 4.8652 4.1544
MDA-MB-436 GDSC1 6.5763 11.6669 2.315 8.081
HCC202 GDSC1; CTRP2 6.6115 17.7347 0.6649 20.0211
Hs 578Bst CTRP2 6.7308 12.4977 3.3704 9.9384
KPL-1 CTRP2 6.7911 8.4426 5.3957 1.5776
MDA-MB-157 GDSC1 6.8152 8.6123 3.7358 0.4228
UACC-893 GDSC1 6.8199 8.9359 3.6191 0.7741
BT-549 GDSC1; CTRP2 6.8747 16.185 1.6483 16.2729
HCC38 GDSC1; CTRP2 6.9328 13.4435 3.0566 10.8529
HCC1428 GDSC1; CTRP2 6.9648 9.8197 4.8578 3.466
MDA-MB-231 GDSC1; CTRP2 6.9843 10.7989 4.3976 5.3039
CAL-85-1 GDSC1; CTRP2 7.2146 14.7274 2.6354 12.0234
HCC1937 GDSC1; CTRP2 7.3067 14.112 3.0082 10.4155
JIMT-1 GDSC1; CTRP2 7.6632 9.1439 5.5475 0.389
BT 239 CTRP2 4.9222 9.3344 3.3909 13.5135
BT 231 CTRP2 5.7496 11.4586 3.0879 12.9484
BT 145 CTRP2 6.19 10.3736 3.9999 8.3126
BT164 CTRP2 6.2705 9.8536 4.3248 6.8022
BT 112 CTRP2 6.272 9.5174 4.4938 6.0913
BT 498 CTRP2 6.3478 8.8097 4.9057 4.2317
BT 428 CTRP2 6.6884 9.4508 4.8435 3.9322
BT 271 CTRP2 6.7052 8.686 5.2254 2.3564
BT 416 CTRP2 6.7944 10.7698 4.2739 6.1118
BT 248 CTRP2 6.9139 11.6934 3.9077 7.4263
BT 245 CTRP2 6.9262 11.7406 3.8936 7.4642
BT 286 CTRP2 6.9767 11.9649 3.8206 7.6812
BT 172 CTRP2 6.9837 10.0912 4.7402 3.9121
BT 359 CTRP2 7.0124 11.8309 3.9129 7.2454
BT 422 CTRP2 7.0902 14.5468 2.6302 12.2565
BT 131 CTRP2 7.1123 9.7899 4.9693 2.8256
BT 482 CTRP2 7.1313 13.71 3.0754 10.4405
BT 440 CTRP2 7.2279 16.0224 2.0041 14.3686
BT 179 CTRP2 7.2771 12.8421 3.6101 8.0567
BT 216 CTRP2 7.2841 11.1482 4.4371 4.7037
BT 139 CTRP2 7.2883 12.9126 3.5837 8.1457
BT 224 CTRP2 7.4864 12.3952 3.9756 6.2658
BT 320 CTRP2 7.6358 15.6988 2.4707 11.9515
BT147 CTRP2 7.6688 12.3854 4.1041 5.4957
BT 330 CTRP2 7.7385 15.0411 2.8679 10.2708
BT 187 CTRP2 7.9403 12.0209 4.4495 3.8057
BT 228 CTRP2 7.9595 16.1617 2.4794 11.4025
BT 444 CTRP2 9.0314 19.6299 1.5512 13.0798
BT 159 CTRP2 9.5814 20.9369 1.2999 13.1226
BT 504 CTRP2 11.2087 23.7639 1.0299 11.8467
BT 328 CTRP2 11.3846 24.8423 0.6361 12.8099
BT 232 CTRP2 11.5263 26.2049 0.0849 14.2098
BT 333 CTRP2 11.6366 22.7958 1.743 9.1321
BT 340 CTRP2 12.5554 28.563 -0.3614 14.1802
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Tongue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-38 CTRP2 4.8903 9.1593 3.4449 13.3687
Cancer Drug Sensitivity Data Curated from 67 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-466 CTRP2 2.5004 8.6975 1.2295 27.9976
D-423MG GDSC1 3.6801 10.812 0.5276 26.166
D-566MG GDSC1 4.2153 9.9758 1.4056 21.8132
MOG-G-UVW GDSC1 4.3138 5.9954 3.4784 6.6819
MOG-G-CCM GDSC1 4.4989 9.0203 2.1185 16.2678
NMC-G1 GDSC1 4.6818 7.169 3.1861 7.7278
D-392MG GDSC1 5.0517 8.5462 2.7828 9.6553
D-247MG GDSC1 5.2327 8.8878 2.7463 9.3923
KS-1 [Human Krukenberg tumour] GDSC1 5.2931 10.6773 1.9129 14.9815
D283 Med GDSC1; CTRP2 5.3132 6.7747 4.9736 6.1452
GI-1 GDSC1 5.3194 8.5189 2.9853 7.3923
Onda 11 GDSC1 5.3653 8.8213 2.8712 8.1068
LNZTA3WT4 GDSC1 5.4293 8.5505 3.044 6.6736
SNU-489 CTRP2 5.5232 9.6343 3.7986 10.4911
D-336MG GDSC1 5.5248 12.4366 1.2182 18.3976
Hs 683 GDSC1; CTRP2 5.5386 9.2547 4.0004 9.6184
M059J GDSC1 5.5986 8.9466 2.9674 6.8044
SK-MG-1 GDSC1 5.705 8.0858 3.4294 2.9733
M059K CTRP2 5.7171 16.2861 0.6483 21.8423
SNB-75 GDSC1; CTRP2 5.7377 11.3106 3.1516 12.7133
SW1088 GDSC1; CTRP2 5.751 11.7078 2.9646 13.4437
YH-13 GDSC1; CTRP2 5.8311 11.7624 3.0057 13.1157
SF539 GDSC1; CTRP2 5.8453 10.07 3.8634 9.5535
Becker GDSC1; CTRP2 5.8525 11.4522 3.179 12.3694
D-502MG GDSC1 5.9104 10.0893 2.6303 8.4133
Onda 10 GDSC1 6.0487 9.929 2.7935 6.9589
AM-38 GDSC1 6.0821 14.5539 0.5884 19.9616
YKG-1 GDSC1; CTRP2 6.1069 9.4729 4.382 6.8673
LN-405 GDSC1 6.1146 13.0567 1.3433 15.9981
KINGS-1 GDSC1 6.138 11.5904 2.0671 11.5938
SNU-1105 CTRP2 6.1753 16.0581 1.1462 19.3206
D-263MG GDSC1 6.1892 8.0129 3.704 1.0399
D-542MG GDSC1 6.1983 7.8568 3.7679 0.7546
42-MG-BA GDSC1; CTRP2 6.1985 10.5092 3.939 8.5509
GB-1 GDSC1; CTRP2 6.2165 10.91 3.7535 9.2906
KNS-81-FD GDSC1 6.2494 10.4962 2.655 7.4446
DK-MG GDSC1; CTRP2 6.3726 10.1466 4.26 6.889
SF126 GDSC1; CTRP2 6.376 11.5672 3.5542 9.8207
H4 GDSC1 6.3816 12.1802 1.9483 11.7215
LN-18 GDSC1; CTRP2 6.3975 8.0149 5.3357 2.3625
U-118MG GDSC1; CTRP2 6.4573 9.9844 4.4071 6.1247
PFSK-1 GDSC1 6.4699 8.6173 3.5917 1.2859
ONS-76 GDSC1; CTRP2 6.4837 12.0296 3.4096 10.2188
SW1783 GDSC1; CTRP2 6.4961 11.7707 3.5484 9.626
T98G GDSC1; CTRP2 6.5161 9.9375 4.4756 5.7373
GaMG GDSC1; CTRP2 6.7075 12.7465 3.2286 10.5552
CAS-1 GDSC1; CTRP2 6.8033 11.7994 3.7723 8.1676
Daoy GDSC1; CTRP2 6.8224 12.2854 3.5462 9.0626
SNU-201 CTRP2 6.8327 10.9468 4.2151 6.2922
SNU-626 CTRP2 6.8738 10.062 4.6778 4.3273
GOS-3 CTRP2 6.8756 11.0778 4.1824 6.3581
A-172 GDSC1; CTRP2 6.8853 9.3853 5.0121 2.9595
KNS-81 CTRP2 6.9067 11.2457 4.1227 6.5536
SF268 GDSC1; CTRP2 6.9362 11.8244 3.8598 7.5867
KNS-42 GDSC1; CTRP2 6.979 9.793 4.8801 3.3568
8-MG-BA GDSC1; CTRP2 7.0302 10.2607 4.6905 4.0458
CCF-STTG1 CTRP2 7.2169 10.9986 4.4632 4.6941
U-87MG ATCC GDSC1; CTRP2 7.2262 14.3687 2.8214 11.2821
KALS-1 GDSC1; CTRP2 7.3092 16.6985 1.7312 15.2062
KNS-60 CTRP2 7.3534 14.3848 2.1301 8.9083
LN-229 GDSC1; CTRP2 7.5144 12.0829 4.145 5.5477
TM-31 CTRP2 7.5504 10.8519 4.7497 3.1294
SF295 GDSC1; CTRP2 7.6417 14.8861 2.8738 10.4006
GMS-10 CTRP2 8.1979 17.5333 1.9808 12.8519
DBTRG-05MG GDSC1; CTRP2 8.3027 15.5709 3.0064 8.8939
U-251MG GDSC1; CTRP2 9.6707 20.4059 1.6146 11.9642
KG-1-C CTRP2 10.8939 24.406 0.5226 13.759
⏷ Show the Full List of 67 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC24TKB GDSC1 4.7299 8.0592 2.7815 10.6758
ETK-1 GDSC1 5.3552 8.3216 3.1039 6.4248
TGBC1TKB GDSC1 6.9401 15.2993 0.8322 16.529
Cancer Drug Sensitivity Data Curated from 22 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-7 CTRP2 4.4813 7.1828 3.9338 12.4386
MFE-280 GDSC1 4.8513 9.316 2.2512 14.1332
JHUEM-1 CTRP2 5.2155 6.6113 4.9402 6.5377
JHUEM-3 CTRP2 5.2877 10.2429 3.2854 13.1182
AN3-CA GDSC1; CTRP2 5.3023 7.1148 4.8113 6.8191
HEC-59 CTRP2 5.4486 9.6965 3.7009 11.0569
RL95-2 GDSC1; CTRP2 5.6973 8.342 4.5948 6.7978
HEC-151 CTRP2 5.9759 6.8906 5.5629 2.16
ESS-1 GDSC1; CTRP2 5.9867 8.2382 4.899 4.9271
HEC-108 CTRP2 6.3526 8.5413 5.0426 3.6523
MFE-319 GDSC1; CTRP2 6.3529 8.4169 5.1044 3.3943
EN GDSC1; CTRP2 6.5002 8.7852 5.0329 3.4488
HEC-1-A CTRP2 6.511 11.2986 3.7953 8.5789
KLE GDSC1; CTRP2 6.5114 12.2867 3.3034 10.6024
HEC-265 CTRP2 6.526 8.4974 5.1924 2.7516
HEC-6 CTRP2 6.616 8.9395 5.0412 3.2331
HEC-1-B CTRP2 6.8354 12.752 3.3249 9.9418
MFE-296 GDSC1; CTRP2 6.8827 10.8949 4.2773 5.9557
HEC-251 CTRP2 7.2363 11.6868 4.1442 5.9544
HEC-50B CTRP2 7.5489 12.7498 3.8476 6.6875
EFE-184 CTRP2 7.6123 12.6314 3.9482 6.1942
Ishikawa (Heraklio) 02 ER- CTRP2 6.8582 8.7351 5.3017 1.8565
⏷ Show the Full List of 22 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KTCTL-21 GDSC1 3.2206 7.7394 1.6266 24.7307
UO-31 GDSC1; CTRP2 4.0182 8.5956 2.845 17.9229
KTCTL-140 GDSC1 4.0499 9.0681 1.7185 20.5864
KTCTL-26A GDSC1 4.2365 7.2263 2.7979 12.2815
OS-RC-2 GDSC1; CTRP2 4.3908 10.8242 2.1673 19.594
NCC021 GDSC1 4.4577 9.5862 1.8021 18.5063
RXF 393L GDSC1 4.488 9.0699 2.0849 14.9243
CAL-54 GDSC1; CTRP2 4.6633 8.9829 3.3098 14.4581
BB65-RCC GDSC1 4.671 8.3262 2.6027 10.9477
KTCTL-195 GDSC1 4.7194 8.8426 2.3837 13.6406
TK-10 GDSC1 5.0795 7.4483 3.3361 4.8363
KTCTL-13 GDSC1 5.1412 9.8375 2.2136 13.458
SW156 GDSC1 5.1494 10.6581 1.8143 14.5897
BFTC-909 GDSC1 5.1689 7.8858 3.1869 6.297
HA7-RCC GDSC1 5.2631 10.1851 2.1329 12.3189
KTCTL-1M GDSC1 5.3859 10.9498 1.8475 15.1133
KMRC-1 GDSC1; CTRP2 5.8114 10.8147 3.4624 11.2882
A-704 GDSC1 5.8616 11.4689 1.936 13.1682
A-498 GDSC1; CTRP2 5.9925 9.1765 4.4349 6.8658
TUHR4TKB CTRP2 6.0042 10.5755 3.7453 9.7316
LB1047-RCC GDSC1 6.1454 10.544 2.5675 7.4458
SN12C GDSC1 6.2026 10.501 2.6237 6.9799
Caki-2 CTRP2 6.225 9.6745 4.3775 6.6649
LB996-RCC GDSC1 6.4172 8.8555 3.4717 1.7441
TUHR10TKB CTRP2 6.4558 9.7378 4.5284 5.6208
TUHR14TKB CTRP2 6.5516 12.1998 3.3785 10.2232
SW13 GDSC1 6.5766 8.1334 3.8163 0.3213
KMRC-20 GDSC1; CTRP2 6.6301 9.3688 4.8415 4.0319
KMRC-3 CTRP2 6.6414 14.5381 2.2843 14.3807
LB2241-RCC GDSC1 6.6801 8.6421 3.6717 0.6859
786-O GDSC1; CTRP2 6.7879 11.4277 3.9445 7.4834
VMRC-RCW GDSC1; CTRP2 6.8436 10.6525 4.3677 5.6456
769-P GDSC1; CTRP2 7.0347 11.9828 3.8546 7.4481
VMRC-RCZ GDSC1; CTRP2 7.3296 16.9391 1.6275 15.5348
RCC10RGB GDSC1; CTRP2 7.3484 10.7638 4.6629 3.7193
KMRC-2 CTRP2 7.5631 16.4781 2.0328 13.6923
Caki-1 GDSC1; CTRP2 7.6362 14.6395 2.9905 9.9555
SNU-1272 CTRP2 7.8548 12.3908 4.2233 4.7804
ACHN GDSC1; CTRP2 8.7352 15.5974 3.2811 7.2606
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW1463 GDSC1 1.3506 4.1301 1.1295 38.2895
SNU-81 GDSC1 3.7848 9.7412 1.1526 24.9173
LoVo GDSC1; CTRP2 4.3935 8.2029 3.4018 14.7629
SW626 GDSC1 4.4107 7.141 2.9856 10.1987
MDST8 GDSC1; CTRP2 4.5134 8.3236 3.4681 14.1939
LS123 GDSC1; CTRP2 4.7065 8.822 3.4279 13.8772
NCI-H747 GDSC1; CTRP2 4.7384 10.1144 2.8398 16.1625
SW48 GDSC1; CTRP2 4.8093 8.3763 3.738 12.373
COLO 320HSR GDSC1 4.9809 7.1994 3.3884 5.2881
GP2d CTRP2 5.2536 8.6168 4.0516 10.0382
GP5d GDSC1 5.319 9.2023 2.6545 9.8136
COLO 320 CTRP2 5.4613 8.6901 4.2089 8.9192
CCK-81 GDSC1; CTRP2 5.4842 7.5705 4.7758 6.5219
SW837 GDSC1 5.5668 8.3761 3.2145 5.1092
HT115 GDSC1; CTRP2 5.5971 6.7106 5.2916 4.1486
SW948 GDSC1; CTRP2 5.6293 7.9492 4.7273 6.3933
HCT 15 GDSC1; CTRP2 5.6981 6.9071 5.2989 3.8731
CaR-1 GDSC1 5.7448 9.2875 2.9012 6.92
SNU-C1 GDSC1; CTRP2 5.782 6.9919 5.3374 3.5201
SNU-175 GDSC1 5.8966 8.6645 3.2801 3.9593
SK-CO-1 CTRP2 5.9232 7.6312 5.1479 4.009
T84 GDSC1; CTRP2 5.9397 9.9716 3.9929 8.8236
LS1034 GDSC1; CTRP2 5.9473 7.6483 5.1601 3.9088
CW-2 GDSC1; CTRP2 5.9748 9.7985 4.109 8.2683
HCC2998 GDSC1 5.9921 8.4064 3.4463 2.7145
SNU-1040 GDSC1 6.0061 12.3302 1.6197 14.7071
SNU-407 GDSC1; CTRP2 6.0192 9.6697 4.2107 7.7552
C2BBe1 GDSC1; CTRP2 6.0449 11.3846 3.3747 11.187
SNU-C2B GDSC1 6.0487 9.1466 3.1513 4.5227
HT-55 GDSC1; CTRP2 6.0513 7.5853 5.2797 3.201
SW1417 GDSC1; CTRP2 6.2437 9.6097 4.425 6.4316
NCI-H508 CTRP2 6.2484 9.2873 4.5896 5.7323
SNU-C2A CTRP2 6.2534 16.3379 1.0707 19.416
SW1116 GDSC1; CTRP2 6.2794 9.2287 4.6436 5.4498
COLO201 CTRP2 6.3868 7.49 5.5832 1.3687
COLO 678 GDSC1; CTRP2 6.426 8.6415 5.0485 3.5046
OUMS-23 CTRP2 6.4266 9.2205 4.7625 4.6941
KM12 GDSC1; CTRP2 6.44 8.3302 5.2121 2.805
SNU-C5 GDSC1; CTRP2 6.4951 11.3899 3.7374 8.8473
SNU-61 GDSC1; CTRP2 6.5032 9.4823 4.6912 4.8615
SNU-C4 CTRP2 6.5415 7.8003 5.5381 1.3381
LS513 GDSC1; CTRP2 6.5469 9.5287 4.7013 4.7467
RCM-1 [Human ESC] GDSC1; CTRP2 6.5881 7.886 5.5277 1.3194
NCI-H716 GDSC1; CTRP2 6.8215 12.0637 3.6553 8.6176
SW620 GDSC1; CTRP2 6.822 9.938 4.7014 4.3091
CL-11 GDSC1; CTRP2 6.8459 13.6829 2.8708 11.7424
SNU-503 CTRP2 6.9221 13.7371 2.9028 11.4824
HT-29 GDSC1; CTRP2 7.2156 9.2067 5.2997 1.4647
SNU-1033 CTRP2 7.2219 19.5642 0.239 20.182
LS411N GDSC1; CTRP2 7.4264 9.0026 5.4967 0.6498
DLD-1 CTRP2 7.4415 8.4809 5.7043 0.1602
HCC-56 CTRP2 7.4821 8.4221 5.7405 0.0972
LS180 GDSC1; CTRP2 7.4854 11.5262 4.3914 4.6077
HCT 116 GDSC1; CTRP2 7.8601 9.2274 5.5965 0.2183
COLO205 GDSC1; CTRP2 8.1916 9.5387 5.6102 0.1213
RKO GDSC1; CTRP2 9.7316 16.7636 3.3566 5.7927
HCT 8 CTRP2 9.9845 19.2057 2.3859 8.9247
⏷ Show the Full List of 57 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1 3.7315 13.5381 -0.787 32.7729
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-182 CTRP2 1.5477 14.3868 -2.2836 38.816
JHH-1 GDSC1; CTRP2 4.53 8.8666 3.2338 15.0893
Li-7 CTRP2 5.1812 13.3316 1.6586 19.6326
HuH-6 CTRP2 5.2698 8.9564 3.9014 10.6214
SNU-878 CTRP2 5.7319 7.9714 4.8095 5.827
Huh-7 GDSC1 5.9324 8.7546 3.2603 4.0222
SNU-423 GDSC1; CTRP2 5.9568 12.8583 2.5642 14.6182
Hep-G2/C3A GDSC1 6.0359 7.7146 3.7529 0.9629
JHH-5 CTRP2 6.0425 7.9825 5.0738 4.0832
JHH-2 GDSC1; CTRP2 6.2556 8.907 4.7851 4.8996
SNU-398 GDSC1; CTRP2 6.32 8.0077 5.2818 2.7112
Hep-G2 CTRP2 6.3377 8.4331 5.0848 3.5015
JHH-4 GDSC1; CTRP2 6.3379 9.6233 4.4933 5.9747
HuH-1 GDSC1; CTRP2 6.3648 8.4411 5.1014 3.3865
JHH-7 GDSC1 6.3779 7.9757 3.7967 0.4663
SNU-449 GDSC1; CTRP2 6.3795 9.3534 4.6602 5.203
PLC/PRF/5 CTRP2 6.5207 7.8899 5.4821 1.5869
SNU-761 CTRP2 6.6226 11.7563 2.8952 6.8394
Hep 3B2.1-7 GDSC1; CTRP2 6.6678 8.8536 5.1192 2.8376
HLE GDSC1 6.73 8.682 3.6771 0.638
JHH-6 GDSC1; CTRP2 6.7628 8.5226 5.3406 1.8251
SK-HEP-1 GDSC1; CTRP2 7.0332 9.8826 4.8736 3.308
HLF CTRP2 7.1654 13.4577 3.2255 9.785
SNU-886 CTRP2 7.2421 16.405 1.8253 14.989
SNU-475 GDSC1; CTRP2 7.7924 16.6131 2.1366 12.936
SNU-387 GDSC1; CTRP2 9.1384 19.8421 1.5228 13.0193
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 213 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HCC44 GDSC1; CTRP2 3.1577 6.6721 2.7027 20.849
NCI-H64 GDSC1 3.6576 4.1054 3.6425 8.4
NCI-H1184 CTRP2 3.7788 9.8629 2.0273 21.6518
NCI-H520 GDSC1; CTRP2 4.0967 9.3505 2.5801 18.7482
SK-MES-1 GDSC1; CTRP2 4.1268 10.916 1.871 21.3365
EBC-1 GDSC1; CTRP2 4.1583 7.4618 3.4797 15.0773
NCI-H2085 GDSC1; CTRP2 4.2991 10.2401 2.3597 19.0893
NCI-H1341 CTRP2 4.3048 6.1113 4.1273 12.2127
EPLC-272H GDSC1; CTRP2 4.4658 9.6099 2.8208 16.8896
NCI-H146 CTRP2 4.6142 14.6374 0.5047 24.6912
NCI-H1755 GDSC1; CTRP2 4.6184 15.018 0.32 25.2242
IST-SL2 GDSC1 4.7368 15.0458 -0.6983 29.0899
SBC-3 GDSC1 4.7546 7.9147 2.8721 9.9089
NCI-H1304 GDSC1 4.9107 9.6774 2.1176 14.8531
Ms-1 GDSC1 4.9124 6.9934 3.4405 5.0808
LXF 289 GDSC1; CTRP2 4.9721 11.0222 2.6137 16.517
NCI-H446 GDSC1; CTRP2 4.9941 9.0364 3.603 12.4809
NCI-H1568 GDSC1; CTRP2 5.0244 7.8692 4.1868 10.0288
PaCa-3 GDSC1 5.0988 9.5854 2.3062 12.9515
NCI-H2135 GDSC1 5.1133 8.1762 3.0079 7.7928
NCI-H2227 GDSC1 5.1568 10.8934 1.7034 16.7302
NCI-H1703 GDSC1; CTRP2 5.1705 8.9197 3.8264 11.1564
NCI-H1648 GDSC1 5.1785 9.6239 2.3465 12.423
NCI-H2171 GDSC1 5.2059 7.2001 3.5359 3.6336
NCI-H2795 GDSC1 5.2063 10.4408 1.9646 13.5192
COR-L311 GDSC1 5.223 9.1415 2.6155 10.3735
Lu-165 GDSC1 5.2349 8.7149 2.832 8.7568
CPC-N GDSC1 5.2491 8.3186 3.0336 7.2239
NCI-H187 GDSC1 5.2526 8.6285 2.8863 8.3059
Calu-3 GDSC1; CTRP2 5.266 12.0605 2.3654 16.8297
COR-L23 GDSC1 5.3092 9.2119 2.6429 9.9252
HCC33 GDSC1 5.3174 7.9898 3.2365 5.5462
COR-L303 GDSC1 5.3215 10.6006 1.9717 14.5136
NCI-H69 GDSC1; CTRP2 5.3317 7.8856 4.4787 8.0996
NCI-H647 GDSC1; CTRP2 5.3799 11.6092 2.6905 15.3153
HCC827 GDSC1; CTRP2 5.3864 7.8 4.5721 7.5876
NCI-H1437 GDSC1 5.4114 8.9797 2.8266 8.3078
NCI-H1975 GDSC1 5.4151 7.872 3.3542 4.4588
NCI-H82 GDSC1 5.4184 8.1839 3.2104 5.488
HCC2279 CTRP2 5.4206 16.2911 0.3924 23.2375
NCI-H2731 GDSC1 5.4503 8.4455 3.1077 6.1571
SBC-1 GDSC1 5.4505 8.8556 2.9126 7.577
DV-90 CTRP2 5.4618 8.3583 4.3721 8.2409
NCI-H596 GDSC1 5.4638 9.298 2.7092 9.0144
NCI-H1048 GDSC1 5.5145 9.0156 2.8791 7.654
NCI-H1734 GDSC1; CTRP2 5.5343 9.4354 3.9071 10.0162
NCI-H1435 GDSC1; CTRP2 5.5375 7.1492 5.0283 5.362
COR-L105 GDSC1; CTRP2 5.5579 9.4409 3.9254 9.8893
NCI-H1623 GDSC1; CTRP2 5.5598 8.4409 4.4217 7.8174
EMC-BAC-1 GDSC1 5.58 7.8202 3.4767 3.2548
IST-SL1 GDSC1 5.583 7.9605 3.4152 3.6679
LC-1/sq GDSC1 5.601 8.7353 3.0683 5.4314
NCI-H2804 GDSC1 5.6086 8.4078 3.2258 4.935
LC-2/ad GDSC1 5.6829 11.1189 1.98 13.3899
LB647-SCLC GDSC1 5.6858 8.0385 3.4395 3.2996
NCI-H292 GDSC1; CTRP2 5.7175 12.2972 2.6416 14.7994
NCI-H1666 GDSC1; CTRP2 5.7177 14.608 1.4873 19.0888
NCI-H2444 GDSC1; CTRP2 5.7596 7.8092 4.203 2.5404
Lu-139 GDSC1 5.7641 8.2521 3.3888 3.4886
COR-L321 GDSC1 5.7682 9.4068 2.8601 7.154
NCI-H290 GDSC1 5.7866 9.4391 2.8567 7.1333
NCI-H2595 GDSC1 5.796 8.222 3.4201 3.2214
NCI-H513 GDSC1 5.8112 8.1311 3.4685 2.8802
NCI-H1395 CTRP2 5.8473 14.6697 1.5664 18.5459
NCI-H1876 GDSC1 5.86 9.1866 3.0206 5.8133
RERF-LC-MS GDSC1; CTRP2 5.8613 8.7558 4.5333 6.714
NCI-H1944 GDSC1; CTRP2 5.8703 8.5942 4.6216 6.3251
NCI-H1563 GDSC1; CTRP2 5.8769 12.5363 2.6578 14.4113
NCI-H1436 GDSC1 5.8785 7.3326 3.8324 0.752
RERF-LC-Sq1 GDSC1 5.8903 10.124 2.6007 8.6671
DMS 273 GDSC1; CTRP2 5.9041 12.3382 2.7799 13.8738
NCI-H2009 GDSC1; CTRP2 5.9252 8.6582 4.6369 6.1502
NCI-H3255 GDSC1 5.931 8.5138 3.3664 2.9698
DMS 454 CTRP2 5.9362 8.3532 4.7987 5.4486
NCI-H2347 GDSC1 5.9464 12.1202 1.6796 14.5152
NCI-H3122 GDSC1 5.9496 11.1326 2.159 11.4928
NCI-H1693 GDSC1; CTRP2 5.9584 10.8042 3.5924 10.4568
NCI-H526 GDSC1; CTRP2 5.9803 8.98 4.5228 6.5203
Lu-135 GDSC1 5.9814 7.8944 3.656 1.5083
NCI-H1581 GDSC1; CTRP2 5.9823 8.315 4.857 5.1122
COR-L95 GDSC1; CTRP2 5.9871 8.1372 4.9499 4.7122
NCI-H2196 GDSC1; CTRP2 6.0035 8.5931 4.7358 5.5797
Sq-1 CTRP2 6.0164 8.5685 4.759 5.4573
EMC-BAC-2 GDSC1 6.0232 10.0367 2.7273 7.4725
NCI-H1694 GDSC1; CTRP2 6.0285 9.8871 4.1098 8.1603
NCI-H1385 CTRP2 6.0384 9.1792 4.472 6.6204
HCC2935 CTRP2 6.0536 9.4205 4.364 7.0448
NCI-H1573 GDSC1; CTRP2 6.0554 9.4544 4.3485 7.1066
NCI-H841 GDSC1; CTRP2 6.0735 8.2999 4.9408 4.5831
DMS 53 GDSC1; CTRP2 6.0792 7.6316 5.2797 3.1479
NCI-H2141 GDSC1; CTRP2 6.0971 13.0736 2.5736 14.3041
NCI-H23 GDSC1; CTRP2 6.1158 8.1287 5.0611 3.9974
NCI-H1836 GDSC1 6.1182 7.7901 3.7594 0.8575
NCI-H847 GDSC1 6.1207 7.5429 3.8535 0.4875
SBC-5 GDSC1; CTRP2 6.1242 6.9304 5.666 1.4431
NCI-H1092 GDSC1; CTRP2 6.1273 9.7829 4.2438 7.4088
NCI-H345 GDSC1 6.1275 7.1648 3.9896 0.1274
NCI-H748 GDSC1 6.1317 8.5295 3.4662 2.3764
DMS 114 GDSC1; CTRP2 6.1344 9.0917 4.5951 5.9204
NCI-H810 GDSC1; CTRP2 6.1368 8.1884 5.0484 4.0116
NCI-H2591 GDSC1 6.1423 9.2485 3.1593 4.2888
NCI-H2869 GDSC1 6.143 8.3039 3.566 1.7916
NCI-H358 GDSC1; CTRP2 6.1528 9.8361 4.2381 7.3844
NCI-H211 GDSC1; CTRP2 6.1578 10.2833 4.0187 8.2944
NCI-H1781 GDSC1 6.1622 7.7728 3.7847 0.7155
NCI-H2087 GDSC1; CTRP2 6.1841 16.0349 1.1651 19.2403
LOU-NH91 GDSC1; CTRP2 6.1901 12.3269 3.0237 12.3369
Lu-134-A GDSC1 6.1942 8.7506 3.4046 2.6489
ABC-1 GDSC1 6.1984 12.6116 1.6175 14.1978
ChaGo-K-1 GDSC1; CTRP2 6.1991 9.4027 4.4924 6.2309
LK-2 GDSC1 6.2227 8.3807 3.5727 1.6552
NCI-H838 GDSC1; CTRP2 6.2242 8.1685 5.1282 3.5179
NCI-H510A GDSC1 6.2264 9.0557 3.2904 3.2969
NCI-H2029 GDSC1; CTRP2 6.2435 9.0936 4.6824 5.3523
NCI-H2803 GDSC1 6.2458 8.3853 3.5817 1.58
NCI-H2122 GDSC1; CTRP2 6.2854 8.2 5.1603 3.2765
UMC-11 GDSC1 6.2903 7.9393 3.775 0.5867
Calu-6 GDSC1; CTRP2 6.3125 7.9574 5.3011 2.6434
NCI-H1339 CTRP2 6.3177 9.5498 4.5139 5.9246
NCI-H2818 GDSC1 6.342 10.0314 2.9232 4.8904
DMS 79 GDSC1; CTRP2 6.3572 9.5025 4.5686 5.6252
LCLC-97TM1 GDSC1; CTRP2 6.3747 16.4485 1.115 19.0337
NCI-H524 GDSC1 6.3953 8.1607 3.7351 0.7332
NCI-H2722 GDSC1 6.4069 7.9258 3.826 0.4133
COR-L88 GDSC1; CTRP2 6.4119 8.5715 5.0725 3.4282
NCI-H2110 GDSC1; CTRP2 6.4317 8.1009 5.3184 2.3805
RERF-LC-KJ GDSC1 6.4325 13.5769 1.3134 15.3114
NCI-H1155 GDSC1; CTRP2 6.4355 9.6617 4.5505 5.5636
NCI-H1650 GDSC1; CTRP2 6.4369 13.2427 2.7669 12.8951
NCI-H2369 GDSC1 6.4399 8.2404 3.7236 0.7449
EKVX GDSC1; CTRP2 6.4423 10.8238 3.9776 7.9433
LK2 CTRP2 6.4473 7.3398 5.6938 0.8536
IA-LM GDSC1 6.449 8.608 3.586 1.3341
NCI-H1688 GDSC1 6.4551 8.0239 3.8093 0.3916
NCI-H322M GDSC1 6.4631 11.109 2.5034 7.9728
NCI-H2126 CTRP2 6.4649 10.2783 4.2669 6.6967
NCI-H661 GDSC1; CTRP2 6.4697 11.919 3.4536 10.0638
NCI-H522 GDSC1; CTRP2 6.4841 10.4886 4.1773 7.0369
LUDLU-1 CTRP2 6.4894 12.5487 3.1553 11.2443
A-427 GDSC1 6.4975 9.7109 3.1517 3.3148
NCI-H2106 CTRP2 6.5171 11.9443 3.4785 9.8757
NCI-H2170 GDSC1; CTRP2 6.5171 9.238 4.8224 4.2931
MOR/CPR CTRP2 6.5179 7.5969 5.6183 1.0568
NCI-H2342 GDSC1; CTRP2 6.5299 10.1862 4.3629 6.1835
NCI-H209 GDSC1 6.5337 9.0053 3.4661 1.8407
Lu-99A GDSC1 6.5625 9.0578 3.4584 1.6485
NCI-H889 CTRP2 6.5668 10.7436 4.1147 7.1539
HCC95 CTRP2 6.5686 9.2292 4.8649 4.0333
LC-1/sq-SF CTRP2 6.5841 8.507 5.2287 2.5164
RERF-LC-Ad2 CTRP2 6.5866 13.533 2.7418 12.7173
HCC15 GDSC1; CTRP2 6.588 11.5328 3.7391 8.6755
NCI-H226 GDSC1; CTRP2 6.5896 9.5777 4.709 4.6446
NCI-H1105 CTRP2 6.5937 8.7076 5.1382 2.8707
NCI-H2172 GDSC1; CTRP2 6.5962 9.2168 4.8913 3.8803
Lu-99 CTRP2 6.604 11.3049 3.8647 8.1274
NCI-H1770 GDSC1 6.6179 8.0025 3.877 0.2034
NCI-H2081 GDSC1; CTRP2 6.6246 11.7876 3.6409 9.0165
COLO 699 CTRP2 6.6554 18.9363 0.1003 21.6216
NCI-H650 GDSC1; CTRP2 6.6697 10.2321 4.4461 5.603
SW1271 GDSC1; CTRP2 6.6786 9.6007 4.7631 4.2783
NCI-H2405 GDSC1; CTRP2 6.6802 9.6621 4.7342 4.3947
NCI-H727 GDSC1; CTRP2 6.6875 9.718 4.7121 4.4741
PC-14 GDSC1; CTRP2 6.7124 8.5641 5.2883 2.0964
RERF-LC-Ad1 CTRP2 6.7139 7.8396 5.6242 0.8177
COLO 668 GDSC1; CTRP2 6.7163 9.8107 4.6876 4.5294
HCC78 GDSC1; CTRP2 6.7609 12.7326 3.2771 10.2652
A-549 GDSC1; CTRP2 6.7626 10.0643 4.597 4.8296
NCI-H1651 GDSC1; CTRP2 6.7694 11.0984 4.0932 6.8996
NCI-H1373 CTRP2 6.7771 10.9485 4.173 6.5568
NCI-H2461 GDSC1 6.8015 9.0658 3.5622 1.1116
HARA [Human squamous cell lung carcinoma] GDSC1; CTRP2 6.8103 11.0784 4.1337 6.6648
NCI-H2023 GDSC1; CTRP2 6.8186 10.3909 4.4777 5.2325
NCI-H2373 GDSC1 6.8292 8.7108 3.7057 0.558
HCC4006 CTRP2 6.8534 12.0915 3.6657 8.5207
NCI-H196 GDSC1; CTRP2 6.8672 15.1671 2.1493 14.4741
NCI-H1993 GDSC1 6.8719 14.9634 0.9471 16.1239
VMRC-LCD CTRP2 6.8858 10.8955 4.2794 5.9424
NCI-H1915 GDSC1; CTRP2 6.9391 8.736 5.3509 1.5737
NCI-H1793 GDSC1; CTRP2 6.947 15.1135 2.2383 13.9989
NCI-H2228 GDSC1; CTRP2 6.9472 12.8288 3.3721 9.5594
NCI-H1355 GDSC1; CTRP2 7.0034 12.7086 3.4738 9.0526
CAL-12T GDSC1; CTRP2 7.0104 18.9831 0.3614 20.2024
T3M-10 CTRP2 7.0477 12.8446 3.4399 9.1164
NCI-H322 CTRP2 7.0621 8.4893 5.5297 0.8204
HCC366 CTRP2 7.0731 11.4515 4.1428 6.2085
NCI-H1299 GDSC1; CTRP2 7.0914 12.1352 3.8214 7.4931
NCI-H1838 GDSC1; CTRP2 7.0946 10.4745 4.6317 4.1906
HCC1833 CTRP2 7.1106 17.0331 1.4113 16.6679
NCI-H2030 GDSC1; CTRP2 7.1561 15.431 2.2423 13.6156
HCC2108 CTRP2 7.1909 16.4718 1.7526 15.3375
Lu-65 GDSC1; CTRP2 7.2019 11.8913 4.0204 6.5092
HOP-92 GDSC1; CTRP2 7.2122 14.1445 2.9216 10.9132
NCI-H460 GDSC1; CTRP2 7.2379 10.5805 4.6773 3.8096
BEN GDSC1; CTRP2 7.2714 8.1315 5.7646 0.1111
NCI-H1869 GDSC1; CTRP2 7.3791 14.5418 2.8502 10.9159
LCLC-103H GDSC1; CTRP2 7.453 9.0077 5.5072 0.6034
HCC1171 CTRP2 7.4846 20.2829 0.0869 20.1588
HOP-62 GDSC1; CTRP2 7.6141 16.4028 2.1081 13.3329
NCI-H441 GDSC1; CTRP2 7.7504 13.4753 3.6367 7.2345
NCI-H1792 GDSC1; CTRP2 7.8828 13.973 3.4879 7.6309
NCI-H2286 CTRP2 7.8956 16.3862 2.3234 12.0837
NCI-H2291 GDSC1; CTRP2 7.9606 14.6403 3.2196 8.568
RERF-LC-A1 CTRP2 8.1434 16.6989 2.3489 11.6018
SHP-77 GDSC1; CTRP2 8.1755 14.3578 3.5015 7.1653
NCI-H720 GDSC1 8.9631 25.4119 -2.6504 24.4146
HCC1438 CTRP2 9.0273 16.3325 3.123 7.4758
Calu-1 CTRP2 9.2091 16.2642 3.2694 6.7101
HCC1195 CTRP2 9.2635 17.0341 2.9447 7.8329
SK-LU-1 GDSC1; CTRP2 9.3329 17.9694 2.5493 9.1764
SW1573 GDSC1; CTRP2 9.3803 25.0591 -0.8464 19.624
KNS-62 CTRP2 9.8842 17.3802 3.1667 6.2968
HCC1588 CTRP2 10.8069 24.0536 0.6326 13.5466
Hs 888.Lu CTRP2 6.6395 12.5242 3.2861 10.4428
⏷ Show the Full List of 213 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1 5.8 13.8859 0.7089 20.1939
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 3.4778 15.1681 -0.8002 30.8763
Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 4.0258 15.8149 -0.6105 29.0885
A2780 GDSC1; CTRP2 4.0622 7.6708 3.2921 16.0648
IGROV-1 GDSC1; CTRP2 4.886 8.3845 3.8095 11.8967
SNU-119 CTRP2 4.9538 10.3952 2.9045 15.4058
SNU-840 CTRP2 5.112 10.767 2.8672 15.1986
ONCO-DG-1 CTRP2 5.2309 11.5338 2.5954 16.013
JHOM-1 CTRP2 5.4774 11.0833 3.0381 13.7164
OVK18 GDSC1; CTRP2 5.6076 7.4059 4.9724 5.4264
OV7 CTRP2 5.6161 12.8409 2.2829 16.3992
OVCAR-3 GDSC1 5.6592 7.573 3.6291 2.1238
OVTOKO GDSC1; CTRP2 5.833 11.9346 2.9213 13.4516
FU-OV-1 GDSC1; CTRP2 5.926 15.488 1.2235 19.5621
RMG-I GDSC1; CTRP2 5.9604 14.2522 1.8703 17.231
Caov-4 GDSC1 6.015 15.3501 0.1474 22.1121
ES-2 GDSC1 6.0233 7.6864 3.7583 0.95
OC 314 GDSC1; CTRP2 6.22 10.1645 4.1288 7.7168
COV434 CTRP2 6.2899 9.5055 4.5139 5.9744
OAW42 GDSC1; CTRP2 6.3005 8.3029 5.1208 3.415
COV644 CTRP2 6.3232 10.8125 3.8885 8.5302
OAW28 GDSC1; CTRP2 6.3616 13.7821 2.4366 14.3242
OV56 GDSC1; CTRP2 6.3949 8.5863 5.0524 3.5402
COV362 CTRP2 6.431 11.3273 3.7178 9.0435
EFO-27 GDSC1; CTRP2 6.4323 8.9773 4.8874 4.1641
TYK-nu GDSC1; CTRP2 6.4527 8.0411 5.3624 2.168
Kuramochi GDSC1; CTRP2 6.5636 13.8263 2.5772 13.4024
DOV13 GDSC1; CTRP2 6.6234 8.7083 5.1586 2.743
JHOS-2 GDSC1; CTRP2 6.6393 9.7591 4.6565 4.7811
TOV-112D GDSC1; CTRP2 6.6573 8.6608 5.2051 2.5057
Caov-3 GDSC1; CTRP2 6.774 11.9784 3.6614 8.6733
MCAS CTRP2 6.7829 10.1454 4.5721 4.9002
OV-90 GDSC1; CTRP2 6.9709 9.0137 5.2425 1.9461
HEY A8 CTRP2 7.154 11.3213 4.2637 5.5927
TOV-21G GDSC1; CTRP2 7.2471 8.7606 5.5093 0.7379
OVCAR-4 GDSC1; CTRP2 7.2646 11.4454 4.2808 5.3602
SNU-8 CTRP2 7.4702 13.0254 3.659 7.5614
ES2 CTRP2 7.7311 9.0002 5.6286 0.2022
OVCAR-5 GDSC1; CTRP2 7.803 13.8365 3.4987 7.7041
SK-OV-3 GDSC1; CTRP2 7.8693 13.5183 3.6971 6.826
OVKATE GDSC1 8.1052 17.5671 0.5244 15.32
OVISE GDSC1; CTRP2 8.38 13.2694 4.143 4.4439
JHOC-5 CTRP2 8.5271 15.0898 3.3857 7.137
OVSAHO CTRP2 8.5342 22.8774 -0.3979 19.7554
OVCAR-8 GDSC1; CTRP2 9.0637 16.377 3.1254 7.421
EFO-21 GDSC1; CTRP2 9.4609 16.4981 3.3159 6.2429
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
H-STS CTRP2 4.4473 7.3046 3.8478 12.8652
P-STS CTRP2 6.5575 8.9696 4.9843 3.5581
SYO-1 CTRP2 7.2637 14.4289 2.8198 11.2257
Cancer Drug Sensitivity Data Curated from 31 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Yamato-SS CTRP2 4.6363 9.6882 2.9479 15.9742
Aska-SS CTRP2 5.0077 12.1649 2.0824 18.4735
Rh41 GDSC1; CTRP2 4.0154 5.5682 3.9395 13.7771
A-204 GDSC1; CTRP2 4.2655 10.2184 2.3376 19.2561
MES-SA GDSC1 4.7702 6.3139 3.6703 3.7251
G-401 GDSC1; CTRP2 4.7714 10.1556 2.8508 16.0413
EW-8 GDSC1 4.9344 7.3442 3.2858 6.1966
G-402 GDSC1; CTRP2 5.007 9.7735 3.2577 13.8594
Rh18 GDSC1; CTRP2 5.2639 11.9938 2.3966 16.7142
Hs 633.T GDSC1 5.3573 8.0556 3.2314 5.4847
STS-0421 GDSC1 5.6375 8.7654 3.0775 5.9219
Rh30 GDSC1 5.8053 8.0483 3.5015 2.6799
TE 441.T GDSC1; CTRP2 5.8758 8.1399 4.8531 5.3428
SW684 GDSC1 5.9065 6.9683 3.978 0.2233
SW982 GDSC1; CTRP2 5.9751 10.5294 3.7439 9.7941
Tm87-16 CTRP2 6.0039 10.6115 3.727 9.8079
TE 617.T CTRP2 6.0174 7.9196 5.0842 4.0885
VA-ES-BJ GDSC1 6.092 7.8552 3.7226 1.0484
TTC-709 CTRP2 6.258 13.763 2.3616 14.8101
GCT GDSC1; CTRP2 6.3002 9.1177 4.7154 5.1115
SW872 GDSC1 6.3009 9.4849 3.1435 4.0988
BT-16 CTRP2 6.3116 7.6416 5.4561 2.0027
HT-1080 GDSC1; CTRP2 6.4777 7.8158 5.4886 1.6202
MFH-ino GDSC1 6.4932 8.6887 3.574 1.3461
SK-LMS-1 GDSC1; CTRP2 6.6294 12.597 3.2419 10.64
SK-UT-1 GDSC1; CTRP2 6.6543 8.936 5.0699 3.058
KYM-1 GDSC1; CTRP2 6.6822 9.8469 4.645 4.7596
RD GDSC1; CTRP2 6.7687 10.275 4.4981 5.2275
RKN GDSC1; CTRP2 6.8921 10.2187 4.6146 4.5575
Hs 729.T CTRP2 7.0383 12.3382 3.6825 8.1454
BT-12 CTRP2 7.0996 8.0522 5.7253 0.2428
⏷ Show the Full List of 31 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 8 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H GDSC1; CTRP2 4.0831 8.9843 2.7349 18.1831
NCI-H28 GDSC1; CTRP2 5.9805 8.6351 4.6954 5.7946
NCI-H2452 GDSC1; CTRP2 6.4976 11.5577 2.9049 6.9924
MPP 89 GDSC1; CTRP2 6.506 8.9308 4.9654 3.7184
IST-Mes1 GDSC1; CTRP2 6.7671 11.2201 4.0314 7.1593
NCI-H2052 GDSC1; CTRP2 6.8086 11.1345 4.1047 6.7873
JL-1 CTRP2 7.3521 11.8022 4.169 5.6835
ACC-MESO-1 CTRP2 8.5706 17.1895 2.4108 10.7339
⏷ Show the Full List of 8 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 6 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC1; CTRP2 2.7816 7.6193 1.9568 24.67
PC-3 GDSC1 4.5189 9.6653 1.8126 18.217
VCaP GDSC1; CTRP2 5.4923 7.8494 4.6487 7.0271
22Rv1 GDSC1; CTRP2 5.9446 9.8194 4.0731 8.4784
DU145 GDSC1; CTRP2 6.3493 10.1603 4.2347 7.0365
PaCa-3 CTRP2 7.5739 12.6678 3.9044 6.4241
⏷ Show the Full List of 6 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
YD-15 CTRP2 4.7816 9.1495 3.3453 14.0305
A-253 GDSC1 6.1334 8.4371 3.5059 2.1424
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1 4.749 7.9127 2.8688 9.9523
Cancer Drug Sensitivity Data Curated from 42 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HGC-27 GDSC1; CTRP2 4.674 5.7572 4.6163 9.3278
RF-48 GDSC1 4.9381 16.7353 -1.3791 30.4908
SNU-5 GDSC1; CTRP2 5.0464 8.7582 3.7868 11.6067
Fu97 GDSC1; CTRP2 5.0705 9.6816 3.3617 13.2911
23132/87 GDSC1; CTRP2 5.2214 7.8503 4.3889 8.7289
NCI-N87 GDSC1; CTRP2 5.3123 7.9431 4.4325 8.3348
SNU-216 CTRP2 5.3305 8.9312 3.9701 10.2004
SNU-1 GDSC1; CTRP2 5.549 9.1459 4.0636 9.3327
NUGC-4 GDSC1; CTRP2 5.5584 9.2953 3.9981 9.5854
GSS CTRP2 5.6847 7.2659 5.113 4.6696
IM95 GDSC1; CTRP2 5.7389 10.1992 3.7072 10.4205
HuG1-N CTRP2 5.7448 10.6391 3.4928 11.2976
SNU-16 GDSC1; CTRP2 5.7812 6.7098 5.4731 2.9628
SNU-601 CTRP2 5.9039 10.2106 3.843 9.5213
Hs 746.T GDSC1; CTRP2 6.0956 12.1079 3.0552 12.3921
HSC-39 GDSC1 6.1207 7.8056 3.7545 0.8769
SNU-620 CTRP2 6.154 7.1732 5.5685 1.7985
ECC10 GDSC1; CTRP2 6.1592 7.6644 5.3279 2.7972
NUGC-3 GDSC1; CTRP2 6.332 8.9618 4.8179 4.6263
TGBC11TKB GDSC1 6.3412 8.5796 3.5479 1.6431
TMK-1 GDSC1 6.3974 8.3226 3.6745 0.9797
OCUM-1 GDSC1 6.5311 8.7977 3.548 1.4315
SCH GDSC1 6.5314 7.7082 3.9464 0.1073
KATO III CTRP2 6.6603 8.282 5.3879 1.7726
SH-10-TC CTRP2 6.7255 8.8015 5.1838 2.4947
MKN7 GDSC1; CTRP2 6.7491 8.9474 5.1299 2.6778
SNU-668 CTRP2 6.7769 11.162 4.0674 6.9937
MKN28 GDSC1 6.8491 9.4771 3.4227 1.704
GCIY GDSC1 6.9152 9.207 3.5564 1.0417
KE-39 CTRP2 6.9506 12.5339 3.5204 8.9511
RERF-GC-1B GDSC1 7.0996 10.1761 3.2583 2.2477
ECC12 CTRP2 7.2094 11.8974 4.0228 6.488
LMSU CTRP2 7.212 13.8657 3.059 10.3711
GSU CTRP2 7.3719 8.1089 5.8087 0.0423
MKN45 GDSC1; CTRP2 7.379 8.2599 5.7594 0.094
SNU-719 CTRP2 7.5869 13.8368 3.3469 8.6288
MKN1 GDSC1; CTRP2 7.6283 10.751 4.8434 2.6864
AGS GDSC1; CTRP2 7.7162 12.079 4.2807 4.7366
MKN74 CTRP2 8.2606 17.384 2.0986 12.3323
SNU-685 CTRP2 6.4469 8.9006 4.9362 3.9365
SNG-M GDSC1; CTRP2 6.5763 10.3809 4.3019 6.3582
SNU-1077 CTRP2 7.3567 13.2942 3.4465 8.5902
⏷ Show the Full List of 42 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 18 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
K5 GDSC1 5.2181 8.1798 3.0791 6.9692
TT GDSC1; CTRP2 5.5614 9.0287 4.1328 9.0176
SW579 CTRP2 5.8872 9.069 4.3992 7.2242
HTC-C3 GDSC1 5.9088 12.2964 1.5673 15.2883
FTC-238 CTRP2 5.9956 9.8877 4.0819 8.3414
KMH-2 GDSC1 6.0194 9.8237 2.8241 6.1113
WRO GDSC1 6.0882 7.6539 3.7987 0.7172
CAL-62 GDSC1; CTRP2 6.2628 9.3323 4.5787 5.7517
IHH-4 GDSC1 6.3069 7.8792 3.8039 0.4832
CGTH-W-1 GDSC1; CTRP2 6.4435 8.9144 4.927 3.9807
FTC-133 GDSC1; CTRP2 6.4643 8.112 5.3362 2.2575
ASH-3 GDSC1 6.5209 9.7471 3.1486 3.2972
BHT-101 GDSC1; CTRP2 6.5826 10.886 4.0562 7.3697
8505C GDSC1; CTRP2 6.7839 11.5308 3.8904 7.7132
B-CPAP GDSC1; CTRP2 7.0839 10.3608 4.6791 4.0154
TT2609-C02 GDSC1; CTRP2 7.3141 11.2389 4.4139 4.7541
ML-1 [Human leukemia] GDSC1; CTRP2 7.518 13.8942 3.2695 9.0429
8305C GDSC1; CTRP2 9.108 20.9442 0.9676 14.8711
⏷ Show the Full List of 18 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
UPCI-SCC-090 GDSC1 2.3981 5.5357 1.8003 27.9206
YD-10B CTRP2 3.8632 7.9056 2.9857 17.788
SNU-1214 CTRP2 4.1292 8.182 3.1417 16.4738
DOK GDSC1 4.7275 9.356 2.1344 15.3558
SCC-25 GDSC1; CTRP2 4.8156 9.6079 3.1577 14.7082
BB49-HNC GDSC1 5.0832 10.4709 1.8566 16.0065
BB30-HNC GDSC1 5.3335 8.6111 2.9506 7.6098
NCI-H3118 GDSC1 5.3348 8.5512 2.9803 6.6085
SKN-3 GDSC1 5.3973 9.1527 2.7334 9.0227
JHU-011 GDSC1 5.402 8.9249 2.8465 8.188
PCI-04B GDSC1 5.4185 8.5681 3.0285 6.8147
SNU-1076 CTRP2 5.434 10.3887 3.3447 12.5583
SAS GDSC1 5.5013 9.7947 2.4952 10.4332
HO-1-N-1 GDSC1 5.5635 8.528 3.1416 5.6382
PCI-15A GDSC1 5.6284 8.1379 3.3615 3.9438
SCC-15 GDSC1 5.6809 9.3902 2.8111 6.9172
BICR 56 CTRP2 5.7436 13.4083 2.1089 16.7918
OSC-19 GDSC1 5.7794 11.6981 1.7666 14.4564
SAT [Human HNSCC] GDSC1 5.8534 10.7831 2.2614 11.0721
BICR 31 GDSC1; CTRP2 5.861 10.5315 3.6463 10.4265
LB771-HNC GDSC1 5.8818 9.1938 3.0306 5.695
CAL-27 GDSC1; CTRP2 5.8975 9.6347 4.1254 8.3523
JHU-022 GDSC1 5.9044 11.4519 1.9741 12.8089
HSC-2 GDSC1; CTRP2 5.9748 6.6219 5.6957 1.6057
KON GDSC1 6.0184 7.9759 3.6404 1.546
BICR 18 CTRP2 6.0678 9.4345 4.3688 6.9973
BICR 78 GDSC1 6.1402 8.3992 3.5252 2.0231
CAL-33 GDSC1; CTRP2 6.1448 9.42 4.4396 6.5539
HSC-4 GDSC1; CTRP2 6.1587 8.7847 4.7683 5.147
Detroit 562 GDSC1; CTRP2 6.1618 8.9618 4.6823 5.5027
HSC-3 GDSC1; CTRP2 6.1705 7.5193 5.4092 2.4364
OSC-20 GDSC1 6.1932 10.7798 2.4875 7.8377
SNU-1066 CTRP2 6.2106 10.4538 3.9767 8.371
PE/CA-PJ49 CTRP2 6.2116 9.7081 4.35 6.8052
Ca9-22 GDSC1 6.2574 9.0254 3.32 3.0629
PE/CA-PJ15 GDSC1; CTRP2 6.2696 11.9942 3.2551 11.247
YD-8 CTRP2 6.321 11.684 3.4517 10.345
PCI-06A GDSC1 6.3258 8.7886 3.4549 2.1659
BICR 22 GDSC1; CTRP2 6.3472 8.9536 4.8338 4.5333
PCI-38 GDSC1 6.3479 8.3511 3.6419 1.1722
HO-1-u-1 GDSC1 6.3623 8.0209 3.7738 0.546
BHY GDSC1; CTRP2 6.3841 10.4775 4.1042 7.5198
PE/CA-PJ34 (clone C12) CTRP2 6.474 8.8345 4.9892 3.6721
BICR 6 CTRP2 6.6248 9.9937 4.5301 5.3285
SNU-899 CTRP2 6.7038 11.6672 3.7618 8.3801
PCI-30 GDSC1 6.7449 9.7241 3.2731 2.3381
FaDu GDSC1; CTRP2 6.7672 9.5914 4.8312 3.862
BICR 10 GDSC1 7.0144 8.6542 3.7946 0.2496
SCC-4 GDSC1; CTRP2 7.166 12.6908 3.6033 8.2609
BICR 16 CTRP2 7.4833 14.7917 2.8043 10.9238
SNU-46 CTRP2 7.5142 18.4384 1.0256 17.2411
SNU-1041 CTRP2 7.5609 15.4795 2.5232 11.875
PE/CA-PJ41 (clone D2) CTRP2 7.6241 15.4263 2.596 11.4956
SCC-9 GDSC1; CTRP2 7.779 14.6637 3.0809 9.3813
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-BLC1 CTRP2 4.9899 10.3579 2.9562 15.1166
5637 GDSC1; CTRP2 5.1908 9.483 3.5706 12.1629
UM-UC-3 GDSC1; CTRP2 5.7398 10.9863 3.3152 12.0399
SCaBER CTRP2 5.7512 9.8881 3.8731 9.704
TCCSUP GDSC1; CTRP2 5.896 9.8203 4.0314 8.7494
JMSU-1 CTRP2 5.9172 9.0037 4.4574 6.9202
253J-BV CTRP2 5.9995 7.567 5.2454 3.4462
VM-CUB-1 CTRP2 6.0123 7.6094 5.235 3.4645
SW780 GDSC1 6.2333 7.6894 3.8443 0.4506
RT-4 GDSC1; CTRP2 6.2588 7.9901 5.2439 2.9728
BC-3C CTRP2 6.3721 11.6965 3.4866 10.1067
CAL-29 GDSC1; CTRP2 6.3931 8.9136 4.889 4.2237
BFTC-905 GDSC1 6.3931 21.3842 -2.5506 29.5959
SW1710 GDSC1; CTRP2 6.493 13.7822 2.5427 13.6671
HT-1376 GDSC1; CTRP2 6.7089 9.1638 4.9978 3.2703
647V GDSC1; CTRP2 6.7305 10.7267 4.2476 6.3252
KMBC-2 CTRP2 6.9447 11.106 4.2191 6.0968
RT-112 GDSC1; CTRP2 6.9802 10.1716 4.699 4.0835
KU-19-19 GDSC1; CTRP2 7.018 8.8215 5.3588 1.4575
639V GDSC1; CTRP2 7.1167 8.2414 5.659 0.3959
HT-1197 GDSC1; CTRP2 7.1964 10.3462 4.7612 3.5332
J82 GDSC1; CTRP2 7.5691 10.9641 4.7093 3.2612
UM-UC-1 CTRP2 7.9153 9.8431 5.3857 0.6549
T24 GDSC1; CTRP2 11.2121 22.5056 1.6181 10.0082
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
BPH-1 GDSC1 2.977 6.6157 1.9247 24.0474
SW954 GDSC1 4.3382 9.594 1.6995 19.5936
PA-1 GDSC1 4.3765 9.1998 1.9283 17.9899
OVMIU GDSC1 4.4057 8.1105 2.497 13.9178
KGN GDSC1 4.6881 10.4154 1.5747 19.0868
ACC-OV7 GDSC1 4.697 8.1598 2.7059 11.3534
Ca Ski GDSC1 4.7569 9.5908 2.0406 15.889
JAR GDSC1 5.268 10.8582 1.8048 15.7465
SKN GDSC1 5.2913 12.9994 0.7622 19.8484
SW962 GDSC1 5.5545 10.512 2.1842 12.4177
NT2-D1 GDSC1 5.5599 9.7788 2.5436 9.9307
OV17R GDSC1 5.5738 14.4057 0.2815 22.8167
SiSo GDSC1 5.7244 7.8981 3.5231 2.682
NCC-IT GDSC1 5.7468 12.1799 1.5079 16.0999
JHOS-3 GDSC1 5.7777 9.1682 2.9779 6.3001
C-33 A GDSC1 5.8053 7.8674 3.5795 2.1955
JEG-3 GDSC1 5.8097 7.5222 3.7259 1.3469
PEO1 GDSC1 5.8311 9.1051 3.0405 5.7392
ME-180 GDSC1 5.8346 9.0199 3.0819 5.4427
OMC-1 [Human cervical carcinoma] GDSC1 5.8891 8.5836 3.312 3.7611
HEY GDSC1 6.0226 8.3233 3.4977 2.3531
SiHa GDSC1 6.0865 7.5747 3.8279 0.6036
DSH1 GDSC1 6.1522 8.5093 3.4851 2.2359
HEC-1 GDSC1 6.1719 7.7719 3.789 0.6908
OVCA420 GDSC1 6.204 8.1417 3.66 1.2328
NEC8 GDSC1 6.2329 7.5414 3.8973 0.2948
SW756 GDSC1 6.2539 7.8035 3.8107 0.5518
C-4-I GDSC1 6.341 7.7947 3.8479 0.382
UWB1.289 GDSC1 6.3604 11.0486 2.4676 8.4402
HT-3 GDSC1 6.3904 8.2628 3.6945 0.9009
OVCA433 GDSC1 6.4154 9.9944 2.9819 4.9305
SKG-IIIa GDSC1 6.4347 8.1773 3.7451 0.6676
DoTc2 4510 GDSC1 6.4413 8.596 3.5873 1.3359
CAL-39 GDSC1 6.5898 8.9101 3.53 1.4569
MS751 GDSC1 6.5911 8.7578 3.5902 1.1762
LB831-BLC GDSC1 6.8564 9.7348 3.3225 2.2043
HeLa GDSC1; CTRP2 6.9683 8.0367 5.6723 0.4515
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Idelalisib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
GDC-0199 DMH0QKA Major Decreased metabolism of Idelalisib caused by GDC-0199 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [11]
Coadministration of a Drug Treating the Disease Different from Idelalisib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [12]
Sarecycline DMLZNIQ Moderate Decreased clearance of Idelalisib due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [13]
Ivosidenib DM8S6T7 Major Decreased metabolism of Idelalisib caused by Ivosidenib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [14]
Tagraxofusp DM9HQ5U Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Tagraxofusp. Acute myeloid leukaemia [2A60] [13]
Arn-509 DMT81LZ Major Accelerated clearance of Idelalisib due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [13]
Gilteritinib DMTI0ZO Major Decreased metabolism of Idelalisib caused by Gilteritinib mediated inhibition of CYP450 enzyme. Acute myeloid leukaemia [2A60] [15]
Oliceridine DM6MDCF Major Decreased metabolism of Idelalisib caused by Oliceridine mediated inhibition of CYP450 enzyme. Acute pain [MG31] [16]
Inotersen DMJ93CT Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Inotersen. Amyloidosis [5D00] [13]
Ivabradine DM0L594 Major Decreased metabolism of Idelalisib caused by Ivabradine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [12]
Troleandomycin DMUZNIG Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Troleandomycin. Bacterial infection [1A00-1C4Z] [13]
Ag-221 DMS0ZBI Moderate Decreased clearance of Idelalisib due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [12]
Pexidartinib DMS2J0Z Major Decreased metabolism of Idelalisib caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [17]
HKI-272 DM6QOVN Major Decreased metabolism of Idelalisib caused by HKI-272 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [18]
LY2835219 DM93VBZ Major Decreased metabolism of Idelalisib caused by LY2835219 mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [19]
Palbociclib DMD7L94 Major Decreased metabolism of Idelalisib caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [20]
Fenofibric acid DMGO2MC Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Fenofibric acid. Cardiovascular disease [BA00-BE2Z] [13]
PF-04449913 DMSB068 Major Decreased metabolism of Idelalisib caused by PF-04449913 mediated inhibition of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [21]
Vilanterol DMF5EK1 Moderate Decreased metabolism of Idelalisib caused by Vilanterol mediated inhibition of CYP450 enzyme. Chronic obstructive pulmonary disease [CA22] [22]
Intedanib DMSTA36 Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Intedanib. Colorectal cancer [2B91] [13]
Osilodrostat DMIJC9X Major Decreased metabolism of Idelalisib caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [23]
MK-8228 DMOB58Q Moderate Decreased metabolism of Idelalisib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [13]
Polatuzumab vedotin DMF6Y0L Major Decreased metabolism of Idelalisib caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [24]
Ingrezza DMVPLNC Major Additive CNS depression effects by the combination of Idelalisib and Ingrezza. Dystonic disorder [8A02] [25]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Idelalisib caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [13]
Cannabidiol DM0659E Minor Decreased metabolism of Idelalisib caused by Cannabidiol mediated inhibition of CYP450 enzyme. Epileptic encephalopathy [8A62] [23]
Bay 80-6946 DMLOS5R Major Decreased clearance of Idelalisib due to the transporter inhibition by Bay 80-6946. Follicular lymphoma [2A80] [26]
Tazemetostat DMWP1BH Major Decreased metabolism of Idelalisib caused by Tazemetostat mediated inhibition of CYP450 enzyme. Follicular lymphoma [2A80] [27]
Ripretinib DM958QB Major Decreased metabolism of Idelalisib caused by Ripretinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [12]
Avapritinib DMK2GZX Major Decreased metabolism of Idelalisib caused by Avapritinib mediated inhibition of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [23]
Daclatasvir DMSFK9V Major Decreased metabolism of Idelalisib caused by Daclatasvir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [23]
177Lu-DOTATATE DMT8GVU Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and 177Lu-DOTATATE. Hepatitis virus infection [1E50-1E51] [13]
GS-9857 DMYU6P5 Moderate Decreased clearance of Idelalisib due to the transporter inhibition by GS-9857. Hepatitis virus infection [1E50-1E51] [28]
MK-1439 DM215WE Minor Decreased metabolism of Idelalisib caused by MK-1439 mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [29]
Fostemsavir DM50ILT Moderate Decreased metabolism of Idelalisib caused by Fostemsavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [30]
Cobicistat DM6L4H2 Moderate Decreased clearance of Idelalisib due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [13]
Levamlodipine DM92S6N Moderate Decreased metabolism of Idelalisib caused by Levamlodipine mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [31]
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [13]
TP-434 DM5A31S Minor Decreased metabolism of Idelalisib caused by TP-434 mediated inhibition of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [32]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Idelalisib caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [13]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Idelalisib caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [33]
Eluxadoline DMYZ0P1 Moderate Decreased metabolism of Idelalisib caused by Eluxadoline mediated inhibition of CYP450 enzyme. Irritable bowel syndrome [DD91] [34]
Pemigatinib DM819JF Major Decreased metabolism of Idelalisib caused by Pemigatinib mediated inhibition of CYP450 enzyme. Liver cancer [2C12] [23]
Brigatinib DM7W94S Major Decreased metabolism of Idelalisib caused by Brigatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [35]
Ceritinib DMB920Z Major Decreased metabolism of Idelalisib caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [12]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Idelalisib caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [36]
PF-06463922 DMKM7EW Major Decreased metabolism of Idelalisib caused by PF-06463922 mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [37]
Alectinib DMP1I6Y Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Alectinib. Lung cancer [2C25] [13]
Osimertinib DMRJLAT Major Decreased metabolism of Idelalisib caused by Osimertinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [38]
Pralsetinib DMWU0I2 Major Decreased metabolism of Idelalisib caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [39]
Capmatinib DMYCXKL Major Decreased metabolism of Idelalisib caused by Capmatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [40]
Selpercatinib DMZR15V Major Decreased metabolism of Idelalisib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [23]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [13]
Acalabrutinib DM7GCVW Major Decreased metabolism of Idelalisib caused by Acalabrutinib mediated inhibition of CYP450 enzyme. Mature B-cell lymphoma [2A85] [41]
Arry-162 DM1P6FR Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Arry-162. Melanoma [2C30] [13]
Selumetinib DMC7W6R Major Decreased metabolism of Idelalisib caused by Selumetinib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [42]
LGX818 DMNQXV8 Major Decreased metabolism of Idelalisib caused by LGX818 mediated inhibition of CYP450 enzyme. Melanoma [2C30] [43]
Ubrogepant DM749I3 Major Decreased metabolism of Idelalisib caused by Ubrogepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [44]
Rimegepant DMHOAUG Moderate Decreased metabolism of Idelalisib caused by Rimegepant mediated inhibition of CYP450 enzyme. Migraine [8A80] [45]
Lasmiditan DMXLVDT Moderate Decreased clearance of Idelalisib due to the transporter inhibition by Lasmiditan. Migraine [8A80] [46]
Siponimod DM2R86O Major Decreased metabolism of Idelalisib caused by Siponimod mediated inhibition of CYP450 enzyme. Multiple sclerosis [8A40] [12]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Idelalisib and Ocrelizumab. Multiple sclerosis [8A40] [47]
Ozanimod DMT6AM2 Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Ozanimod. Multiple sclerosis [8A40] [13]
Deflazacort DMV0RNS Major Decreased metabolism of Idelalisib caused by Deflazacort mediated inhibition of CYP450 enzyme. Muscular dystrophy [8C70] [23]
Fedratinib DM4ZBK6 Major Decreased metabolism of Idelalisib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [23]
Entrectinib DMMPTLH Major Decreased metabolism of Idelalisib caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [12]
S-297995 DM26IH8 Moderate Decreased metabolism of Idelalisib caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [23]
Olaparib DM8QB1D Major Decreased metabolism of Idelalisib caused by Olaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [12]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Idelalisib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [48]
Istradefylline DM20VSK Major Decreased metabolism of Idelalisib caused by Istradefylline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [49]
Abametapir DM2RX0I Moderate Decreased metabolism of Idelalisib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [50]
Lefamulin DME6G97 Major Decreased clearance of Idelalisib due to the transporter inhibition by Lefamulin. Pneumonia [CA40] [51]
Darolutamide DMV7YFT Moderate Decreased clearance of Idelalisib due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [52]
Upadacitinib DM32B5U Major Decreased metabolism of Idelalisib caused by Upadacitinib mediated inhibition of CYP450 enzyme. Rheumatoid arthritis [FA20] [53]
Sarilumab DMOGNXY Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Sarilumab. Rheumatoid arthritis [FA20] [13]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Idelalisib when combined with Anthrax vaccine. Sepsis [1G40-1G41] [54]
Voxelotor DMCS6M5 Major Decreased metabolism of Idelalisib caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [55]
LDE225 DMM9F25 Major Decreased metabolism of Idelalisib caused by LDE225 mediated inhibition of CYP450 enzyme. Skin cancer [2C30-2C37] [56]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Idelalisib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [23]
Larotrectinib DM26CQR Major Decreased metabolism of Idelalisib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [12]
LEE011 DMMX75K Major Decreased metabolism of Idelalisib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [57]
Fostamatinib DM6AUHV Major Decreased metabolism of Idelalisib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [58]
Lusutrombopag DMH6IKO Moderate Decreased clearance of Idelalisib due to the transporter inhibition by Lusutrombopag. Thrombocytopenia [3B64] [48]
As-1670542 DMV05SW Moderate Decreased metabolism of Idelalisib caused by As-1670542 mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [23]
Lenvatinib DMB1IU4 Moderate Increased risk of hepatotoxicity by the combination of Idelalisib and Lenvatinib. Thyroid cancer [2D10] [13]
Elagolix DMB2C0E Major Decreased metabolism of Idelalisib caused by Elagolix mediated inhibition of CYP450 enzyme. Uterine fibroid [2E86] [59]
Fluticasone DMGCSVF Major Decreased metabolism of Idelalisib caused by Fluticasone mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [60]
⏷ Show the Full List of 86 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Magnesium stearate E00208 11177 lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Idelalisib 100 mg tablet 100 mg Oral Tablet Oral
Idelalisib 150 mg tablet 150 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6741).
2 Idelalisib FDA Label
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
5 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB09054)
6 FDA label of Idelalisib. The 2020 official website of the U.S. Food and Drug Administration.
7 Roles of pulmonary telocytes in airway epithelia to benefit experimental acute lung injury through production of telocyte-driven mediators and exosomes. Cell Biol Toxicol. 2023 Apr;39(2):451-465. doi: 10.1007/s10565-021-09670-5. Epub 2022 Jan 3.
8 Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3K inhibition through PIK3IP1. Cell Cycle. 2013 Jun 15;12(12):1892-900. doi: 10.4161/cc.24928. Epub 2013 May 15.
9 Regulatory roles of NAT10 in airway epithelial cell function and metabolism in pathological conditions. Cell Biol Toxicol. 2023 Aug;39(4):1237-1256. doi: 10.1007/s10565-022-09743-z. Epub 2022 Jul 25.
10 PI3K/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicol Appl Pharmacol. 2019 Oct 15;381:114729. doi: 10.1016/j.taap.2019.114729. Epub 2019 Aug 22.
11 Product Information. Venclexta (venetoclax). AbbVie US LLC, North Chicago, IL.
12 Cerner Multum, Inc. "Australian Product Information.".
13 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
14 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
15 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
16 Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
17 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
18 Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7. [PMID: 21395644]
19 Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
20 Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
21 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
22 Product Information. Breo Ellipta (fluticasone-vilanterol). GlaxoSmithKline, Research Triangle Park, NC.
23 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
24 Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
25 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
26 Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
27 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
28 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
29 Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
30 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
31 Canadian Pharmacists Association.
32 Product Information. Xerava (eravacycline). Tetraphase Pharmaceuticals, Inc, Watertown, MA.
33 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
34 Product Information. Viberzi (eluxadoline). Actavis Pharma, Inc., Parsippany, NJ.
35 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
36 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
37 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
38 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
39 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
40 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
42 Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
43 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
44 Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
45 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
46 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
47 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
48 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
49 Product Information. Nourianz (istradefylline). Kyowa Kirin, Inc, Bedminster, NJ.
50 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
51 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
52 Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
53 Product Information. Rinvoq (upadacitinib). AbbVie US LLC, North Chicago, IL.
54 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
55 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
56 Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
57 Product Information. Kisqali (ribociclib). Novartis Pharmaceuticals, East Hanover, NJ.
58 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
59 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
60 Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048. [PMID: 17072128]